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CHAPTER 1 GPI ANCHORING OF PROTEINS AND GPI TRANSAMIDASE 
1.1 Introduction 
Glycosylphosphatidylinositol (GPI) anchoring of proteins is a common and complex 
post-translational modification. It is predicted that ~0.5% of all eukaryotic proteins are 
modified at their C-termini to become covalently or non-covalently associated with the 
cell surface via a GPI anchor.1 GPI-anchored proteins (GPI-APs) play important roles in 
cell adhesion and development, signaling pathways, regulation of the complement 
system, and other fundamental cellular processes.2, 3 Human GPI-APs, including the 
urokinase-type plasminogen activator receptor (uPAR) and the folate receptor, are 
biomarkers for many different cancers.4 Protozoan GPI-APs, such as the variant surface 
glycoprotein (VSG) expressed in Trypanosoma brucei (T. brucei), allow the parasite to 
evade the host’s immune system.5 The loss of GPI anchoring of proteins is 
embryonically lethal in mice and conditionally lethal to yeast.6, 7 While GPI anchoring of 
proteins is an essential process and the functions of many GPI-APs are characterized, 
our understanding of GPI transamidase (GPI-T), the enzyme that catalyzes this post-
translational modification, has been slow to emerge.4 
GPI-T, a multisubunit, membrane-bound enzyme localized in the endoplasmic 
reticulum (ER), catalyzes the addition of the GPI anchor based on a C-terminal signal 
sequence, which is recognized, cleaved, and replaced by the GPI anchor (Figure 1.1).4 
There are five known subunits that assemble to form the Saccharomyces cerevisiae (S. 
cerevisiae) GPI-T: Gaa1, Gpi8, Gpi16, Gpi17, and Gab1 (the human orthologs are 
GPAA1, PIG-K, PIG-T, PIG-S, and PIG-U, respectively).8-14 Gpi8/PIG-K contains most or 
all of GPI-T’s active site and the functions of the other subunits are largely unclear or 
speculative.15 Within the last decade, aberrant expression of individual GPI-T subunits 
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has been observed in a myriad of cancers.16 It is necessary to investigate the assembly 
and stoichiometry of GPI-T, as well as the functions of each subunit, to understand the 
roles of this enzyme in normal cell function, and cancer initiation and metastasis. 
 
Figure 1.1. The chemical structure of the S. cerevisiae GPI anchor and the net 
reaction catalyzed by GPI-T. a) Left: The S. cerevisiae GPI anchor is composed of a 
phosphatidylinositol moiety (n = 16-24), one glucosamine, and four mannoses.4 An 
ethanolamine phosphate, attached to the third mannose, links the GPI anchor to the 
protein via an amide bond.3, 17 Right: A cartoon representation of the S. cerevisiae GPI 
anchor. b) GPI-T displaces the C-terminal signal sequence from a newly synthesized 
protein with a fully formed GPI anchor precursor in the endoplasmic reticulum (ER). A 
new amide bond is formed between the ethanolamine phosphate amine on the third 
mannose in the GPI anchor and the α-carbonyl group of the new C-terminus (the ω-site). 
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1.2 Discovery of GPI-anchored proteins 
The bacterial phosphatidylinositol-specific phospholipase C (PI-PLC) was able to 
release alkaline phosphatase from slices and homogenates of mammalian tissues.18, 19 
Other eukaryotic membrane-bound proteins were similarly converted into soluble 
proteins, including acetylcholinesterase and VSG, upon treatment with PI-PLC.20 It was 
proposed that these proteins were covalently attached to the cell surface via a 
phosphatidylinositol group.20 
Early research on VSG demonstrated that the hydrophobic C-terminus of this protein 
was absent from the isolated, membrane-bound form (mfVSG).21, 22 VSG was digested 
with trypsin and Pronase, a commercial mixture of different proteases, for amino acid 
sequencing and glycopeptides were purified, including a C-terminal fragment;23 Edman 
degradation revealed that an ethanolamine was attached, via an amide bond, to the C-
terminus of mfVSG.24 Fatty acids were hydrolyzed from mfVSG and converted to their 
methyl esters; gas-liquid chromatography showed that one equivalent of myristic acid 
was release for every equivalent of VSG.25 Further characterization of the C-terminus of 
mfVSG versus soluble VSG demonstrated that two equivalents of myristic acid were 
present.26 This result was confirmed by the release of 1,2-dimyristylglycerol after PI-PLC 
digestion of mfVSG, demonstrating a novel glycolipid anchor for eukaryotic proteins.26, 27 
Shortly after these discoveries, the full-length structure of the GPI anchor of VSG 
was reported after enzymatic digestions, chemical modifications, and nuclear magnetic 
resonance and mass spectrometric analyses.28 Treatment of GPI-VSG with PI-PLC 
hydrolyzed and released soluble VSG from diacylglycerol. VSG was digested with 
Pronase to peptide fragments. The ω-site residue, ethanolamine phosphate, and amino 
group from glucosamine were removed by sodium nitrite deamination, sodium 
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borohydride reduction, and HF hydrolysis. These enzymatic and chemical modifications 
yielded the glycan backbone of VSG’s GPI anchor. Within the same year, the structure 
of the GPI anchor of rat brain Thy-1 was determined using similar methods.29 These 
reports identified a core structure present in both GPI anchors, composed of a 
phosphatidylinositol moiety, one glucosamine, three mannoses, and the ethanolamine 
phosphate on the third mannose for attachment to the protein substrate (Figure 1.2). The 
GPI anchor of VSG is shown (Figure 1.2a) with that of Thy-1 (Figure 1.2b) for 
comparison. The structures of many GPI anchors have since been reported and this 
core structure remains conserved. Further modifications to the GPI anchor are present in 
species- and tissue-specific manners, discussed further in section 1.3.2.3, 17 
 
Figure 1.2. The chemical structures of the mature GPI anchors of a) T. brucei VSG 
and b) rat brain Thy-1. The GPI anchor core structure, shown in black, is composed of 
a phosphatidylinositol moiety (n = 12-26 in mammals and protozoa), one glucosamine, 
three mannoses, and an ethanolamine phosphate which links the GPI anchor to the 
protein substrate.4 Panel a shows the GPI anchor of VSG with its two appended 
galactoses in red.28 Panel b shows the structure of the GPI anchor of Thy-1 with an 
additional ethanolamine phosphate, mannose, and galactose, all shown in blue.29 
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1.3 The GPI anchor substrate for GPI-T 
Biosynthesis of the GPI anchor, its transfer to a protein substrate, and the 
modifications that take place after GPI attachment to proteins requires more than 20 
gene products.30 The biosynthetic steps are conserved among many species, which will 
be highlighted in the following section.17 Additional modifications to the glycans and lipid 
chains may be present, which will be discussed in sections 1.3.2 and 1.6, respectively. 
1.3.1 Biosynthesis of the yeast GPI anchor 
GPI anchor biosynthesis begins on the cytosolic face of the ER membrane.30 The 
first step is the transfer of GlcNAc from UDP-GlcNAc to PI to form GlcNAc-PI, catalyzed 
by the UDP-GlcNAc transferase complex (Figure 1.3, step 1). This enzyme is composed 
of several subunits, the S. cerevisiae subunits are listed with the human subunits in 
parentheses: Eri1 (PIG-Y), Gpi1 (PIG-Q), Gpi2 (PIG-C), Gpi3 (PIG-A), Gpi15 (PIG-H), 
Gpi19 (PIG-P), and a seventh subunit found in mammals, DPM2.7, 31-42 Gpi3 is the 
proposed active site of UDP-GlcNAc transferase, because it cross-linked to the α-32P-
labeled photo-reactive UDP-GlcNAc derivative P3-(4-azidoanilido)-uridine 5’-
triphosphate.43 In humans, DPM2, a subunit of the dolichol-phosphate mannose (Dol-P-
Man) synthase, is non-essential, but enhances the activity of UDP-GlcNAc transferase.41 
GlcNAc-PI is then deacetylated to GlcN-PI by Gpi12 (PIG-L) (Figure 1.3, step 2).44, 45  
GPI anchor biosynthesis continues on the lumenal side of the ER indicating the need 
for a flippase, which has continued to elude discovery (Figure 1.3, step 3). After flipping, 
Gwt1 (PIG-W) catalyzes the addition of an acyl chain, generally a palmitoyl group, to the 
inositol ring of GlcN-PI (Figure 1.3, step 4).30, 46, 47 Gpi14 (PIG-M), the GPI 
mannosyltransferase I, transfers mannose from the Dol-P-Man donor to GlcN-acyl-PI to 
form Manα1-4GlcN-acyl-PI (Figure 1.3, step 5).48 Addition of the second mannose to the 
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GPI precursor is catalyzed by Gpi18 (PIG-V) to yield Manα1-6Manα1-4GlcN-acyl-PI 
(Figure 1.3, step 6).49 Next, an ethanolamine phosphate (EtNP) is added to O2 of Man1 
by the GPI EtNP transferase I Mcd4 (PIG-N) (Figure 1.3, step 7).50 In yeast, the addition 
of this EtNP onto Man1 is essential for GPI anchoring of proteins, but this modification is 
absent mature yeast GPI-APs (see section 1.6).51, 52 The EtNP on Man1 is necessary for 
recognition of the GPI anchor by the mammalian GPI-T.53 
The GPI mannosyltransferase III, Gpi10 (PIG-B), adds Man3 to form Manα1-
2Manα1-6Manα1-4GlcN-acyl-PI (Figure 1.3, step 8).54, 55 Next, an EtNP, used for later 
attachment of the GPI precursor onto proteins, is transferred to O6 of Man3 by the GPI 
EtNP transferase III Gpi13 (PIG-O) (Figure 1.3, step 9).56, 57 Lastly, an EtNP is added to 
O6 of Man2 by the GPI EtNP transferase II Gpi17 (hGPI7) and Gpi11 (PIG-F) (Figure 
1.3, step 10). This EtNP is removed after GPI anchor addition to protein substrates.58 A 
fourth mannose is added to Man3 via an α1-2 glycosidic bond (Figure 1.3, step 11).59 
This additional mannose is present in yeast GPI anchors and may be present in other 
species.3, 17 
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Figure 1.3 The GPI anchor biosynthetic pathway in yeast. A cartoon representation 
highlighting the biosynthesis of the GPI anchor precursor.30 Figure adapted from 
reference 30. 
 
1.3.2 Structural diversity of the GPI anchor 
Modifications to the glycan core of the GPI anchor, including the addition of a variety 
of monosaccharides or EtNP substituents, have been reported and have been 
extensively reviewed.3 Biosynthetic steps of the GPI anchor may also vary.17 One 
notable difference is the absence of the EtNP on O2 of Man1 in the GPI anchors from T. 
brucei and Plasmodium falciparum (P. falciparum).28 Interestingly, the Dol-P-Man 
synthase present in P. falciparum did not restore Dol-P-Man biosynthesis in S. 
cerevisiae or mammalian Dol-P-Man synthase knockouts.60 This difference may be an 
attractive therapeutic targeting GPI anchoring of proteins in P. falciparum. In T. brucei’s 
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GPI anchor biosynthetic pathway, acylation of the inositol ring occurs after the addition 
of Man1 and the anchors present in many VSGs contain galactose on Man1.61 
The S. cerevisiae GPI anchor contains four or more mannoses (Figure 1a).62 
Mammalian GPI anchors may contain a variety of different, additional modifications. For 
example, the human lymphocyte CD52 antigen contains an EtNP on the O2 position of 
Man1 and a fourth mannose with an α1-2 glycosidic bond to Man3.63 The GPI anchor of 
prions may contain sialic acid on Man1.3 Recently, the role of GPI anchor sialylation on 
the conversion of the cellular prion protein (PrPC) to the neurodegeneration-related 
scrapie prion (PrPSc) was investigated in cultured neurons.64 Sialylated GPI-PrPC was 
converted to GPI-PrPSc in scrapie-infected neuronal cell lines, while desialylated GPI-
PrPC was not converted to GPI-PrPSc. Interestingly, treatment of scrapie-infected 
neuronal cells with desialylated PrPC resulted in the reduction of PrPSc. These results 
demonstrate the significance of modifications to the GPI anchor in neurodegeneration; 
the inhibition of sialyltransferases may be a potential therapeutic for prion diseases 
including mad cow disease and Creutzfeldt-Jakob disease.64 
1.3.3 GPI-T will accept alternative nucleophiles in vitro and modified GPI anchors 
in vivo 
Early research characterizing the mammalian GPI-T demonstrated the 
transamidation of a truncated GPI-AP upon the incubation of crude microsomes 
(reconstituted membranes of the rough ER) with 10 mM hydroxylamine or hydrazine.65 
Incubation of GPI-VSG with trypanosomes and hydroxylamine, hydrazine, or biotin 
hydrazide also resulted in the release of soluble VSG.66 Streptavidin pull-down of soluble 
VSG after its release with biotin hydrazide demonstrated transamidation and 
biotinylation.67 The ability to use these nucleophiles in place of the GPI anchor simplifies 
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experiments to measure and characterize the activity of GPI-T and will be capitalized 
upon in this dissertation work (see Chapter 2). 
Modified full-length and truncated GPI anchors have been synthesized to assay GPI-
T’s activity, label GPI-APs, and to probe the roles of GPI anchors. Metabolic 
incorporation of an azide-labeled inositol into mature GPI-APs in vivo allowed for their 
detection and visualization.68 Many truncated GPI anchor analogs have been used to 
characterize the activity of and interactions with GPI-T and to investigate interactions 
between the GPI anchor and bacterial toxins such as the CAMP factor.53, 69, 70 Complex 
synthetic strategies have been used to synthesize complete GPI-anchored proteins to 
develop potential cancer vaccines and purifications of native GPI-APs, such as the 
Plasmodium vivax GPI-anchored micronemal antigen (PvGAMA), have been used to 
characterize immune responses and antibody production after parasitic infection.71, 72 
1.4 The protein substrate for GPI-T 
GPI anchoring of proteins is recognized as a common post-translational modification 
and the roles of many GPI-APs have been elucidated.4 Proteins that will be GPI-
anchored are processed prior to and after anchor attachment. Each GPI-T protein 
substrate is synthesized as a preproprotein, containing appropriate N- and C-terminal 
signal sequences, which are recognized for translocation into the ER and GPI anchor 
addition, respectively. The preproprotein is co-translationally translocated into the ER, 
typically via the signal recognition particle (SRP).73 In this case, the SRP recognizes the 
N-terminal signal sequence and interacts with the SRP receptor (SR), allowing the 
preproprotein to enter the ER through the Sec61 translocon. Recently, it was reported 
that preproproteins in S. cerevisiae can also be translocated into the ER in an SRP-
independent manner.74 Proteins involved in this GET (guided-entry of tail-anchored 
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proteins) pathway, including Get1, Get3, and Get5, were necessary for maturation of 
Gas1 to its GPI-anchored form; the Δget1, Δget3, and Δget5 yeast mutants resulted in 
Gas1 aggregation in the cytosol rather than its surface expression.74 Regardless of the 
translocation mechanism, the N-terminal signal sequence is cleaved, processing the 
preproprotein to the proprotein. Following translocation, GPI-T recognizes the C-terminal 
signal sequence in this proprotein, identifying it as a substrate for GPI anchor addition. 
GPI-T catalyzes the cleavage of this C-terminal signal sequence, replacing it with the 
GPI anchor.4 The anchor is linked to the new C-terminal amino acid residue termed the 
ω-site, via an amide bond between the amine of the ethanolamine phosphate on O6 of 
Man3 in the GPI anchor and the α-carbonyl of the ω-site amino acid. 
Early work with GPI-T relied on a cell-free system that used the mammalian enzyme 
in crude, solubilized microsomes and the human GPI-AP placental alkaline phosphatase 
(PLAP).75, 76 To observe relatively small molecular weight changes that result from 
preproprotein processing and GPI anchoring with improved resolution, 60% of the 
internal sequence of PLAP, including the catalytic site, and the glycosylation sites were 
removed, creating preprominiPLAP (~28.0 kDa).77 Processing of preprominiPLAP to 
prominiPLAP (~27.0 kDa) and GPI-miniPLAP (~24.7 kDa), and anchorless miniPLAP 
(~23.0 kDa) were observed by SDS-PAGE after incubation with rough microsomes from 
different mammalian cell lines (Figure 1.4).78 MiniPLAP resulted from hydrolysis of 
prominiPLAP’s C-terminal signal sequence. This method is not suitable for kinetic 
analyses, due to the prolonged incubation time with the rough microsomes and analyses 
by SDS-PAGE and autoradiography, but has largely remained the state-of-the-art assay 
to measure GPI anchoring of proteins. 
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Figure 1.4. A cartoon representation of miniPLAP processing and GPI anchoring 
upon incubation with rough microsomes.77 The N-terminal signal sequence of 
preprominiPLAP is cleaved by signal peptidase upon translocation into the ER. GPI-T 
cleaves and replaces the C-terminal signal sequence of prominiPLAP with a fully formed 
GPI anchor precursor, yielding GPI-miniPLAP. Hydrolysis of the signal sequence from 
prominiPLAP to the anchorless protein has been observed in vitro.78 
 
1.4.1 Specificity at the ω-site 
The miniPLAP in vitro assay was used to characterize GPI-T’s specificity at the ω-
site.77 Site-directed mutagenesis of miniPLAP’s ω-site residue, Asp484, to glycine, 
alanine, serine, cysteine, and asparagine produced proteins that were still processed by 
GPI-T to mature GPI-APs.77 Similar results were reported when the soluble human 
growth hormone (hGH) was expressed with the C-terminal signal sequence of the 
human GPI-AP decay accelerating factor (DAF): Upon transfection into COS cells, 
mature GPI-hGH was produced.79 The Ser319 ω-site in this artificial hGH-DAF construct 
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was mutated to every other encoded amino acid to measure the surface expression of 
hGH for each mutant. Substitution of Ser319 with glycine, alanine, aspartate, and 
asparagine allowed processing of the hGH-DAF fusion to GPI-hGH. These results 
demonstrate that GPI-T will accept a small amino acid at the proprotein’s ω-site. 
The C-terminal signal sequence begins on the C-terminal side of the ω-site starting 
with ω+1, and moving C-terminally to ω+2, ω+3, etc. The amino acid requirements at the 
ω+1 and ω+2 residues were also investigated with the miniPLAP assay.80 Analysis of 
miniPLAP mutations revealed that any amino acid except for proline can be tolerated at 
the ω+1 position. Glycine and alanine were favored at the ω+2 position with trace activity 
for the serine and cysteine mutants. These findings demonstrate GPI-T recognizes a so 
called “small amino acid domain” (SAAD, the ω-site through the ω+2 residue) at the 
proprotein’s cleavage site.4 
1.4.2 The C-terminal signal sequence 
After the SAAD region, the C-terminal signal sequence for GPI-T-mediated 
processing lacks a consensus sequence, but is rather composed of an 8 to 12 amino 
acid hydrophilic spacer followed by a 15 to 20 amino acid hydrophobic region (Table 
1.1).4 In a report using several truncated chimeras of the GPI-AP DAF, the requirements 
for each region of the C-terminal signal sequence were elucidated.81 Truncating the 
hydrophobic portion resulted in secretion, rather than anchoring, of DAF. As discussed in 
the previous section, fusion of the signal sequence to the C-terminus of hGH converted 
this cytosolic protein to a GPI-AP.79 When only the hydrophobic region of DAF’s signal 
sequence was fused to the C-terminus of hGH, this protein was not displayed at the cell 
surface.82 Truncation of DAF’s hydrophilic spacer also reduced the surface expression of 
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GPI-hGH. Together, these results demonstrate that both the hydrophilic and 
hydrophobic regions are necessary for recognition by GPI-T. 
Table 1.1. Examples of C-terminal signal sequences from various GPI-T proprotein 
substrates. GPI-APs from different species are listed with their ω-site and C-terminal 
peptide sequences.76, 81, 83-87 
 
Protein Species ω-site C-terminal signal sequence 
DAF Homo sapiens S GTTRLLSGHTCFTLTGLLGTLVTMGLLT 
PLAP H. sapiens D AAHPGRSVVPALLPLLAGTLLLLETATAP 
CD52 H. sapiens S ASSNISGGIFLFFVANAIIHLFCFS 
uPAR H. sapiens A AAPQPGPAHLSLTITLLMTARLWGGTLLWT 
VSG 117 T. brucei D SSILVTKKFALTVVSAAFVALLF 
Procyclin B1 T. brucei G AATLKSVALPFAIAAAALVAAF 
Gas1 S. cerevisiae N AATNVKANLAQVVFTSIISLSIAAGVGFALV 
Yapsin 2 S. cerevisiae N GGHNLNPPFFARFITAIFHHI 
 
Several other cytosolic and secreted proteins have been converted to GPI-APs by 
the fusion of native signal sequences, including glucose oxidase and invertase (INV) in 
yeast.87, 88 Remarkably, the addition of the artificial C-terminal signal sequence 
Ser3Thr8Leu14 to CD46 was sufficient to convert this membrane protein into a GPI-AP in 
Chinese hamster ovary (CHO) cells.89 
The C-terminal signal sequences of several known yeast and human GPI-APs were 
fused to INV to convert this soluble protein into a substrate for GPI-T.87 These constructs 
were transformed into the S. cerevisiae SEY6210α INV-deficient strain. A glucose 
oxidase colorimetric assay was used to measure GPI-INV activity to correlate to in vivo 
GPI-T activity. The C-terminal signal sequence of human CD52 fused to INV was a poor 
substrate for GPI-T when compared to the yeast GPI-AP Yapsin 2 sequence. INV 
chimeras were constructed where regions of CD52’s signal sequence were replaced 
with that of Yapsin 2 to determine which sub-regions, if any, were necessary for 
recognition by yeast GPI-T. When the (ω+1) – (ω+12) residues of CD52 were fused with 
the (ω+11) – (ω+22) sequence of Yapsin 2, INV activity was restored to ~70% of INV 
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modified with the wild-type Yapsin 2 signal sequence. These residues from the C-
terminal signal sequence of Yapsin 2 may be a determining factor for the yeast GPI-T to 
recognize its proprotein substrate. Altogether, these data demonstrate that GPI-T 
recognizes the C-terminal signal sequence, even when appended to a non-native 
substrate, and although there may be species-specificity variations, neither the 
hydrophilic or hydrophobic region have consensus sequences. 
1.5 The GPI transamidase (GPI-T) complex 
GPI-T is the multimeric enzyme that catalyzes GPI anchor addition to appropriate 
protein substrates.4 GPI anchor attachment to VSG in vitro without added ATP or GTP 
first suggested a transamidation mechanism.90 Conversion of prominiPLAP to mature 
miniPLAP after incubation with rough microsomes and 10 mM hydroxylamine or 10 mM 
hydrazine provided evidence of transamidation of an activated carbonyl intermediate, 
suggesting a protease-like mechanism with an acyl-enzyme intermediate.65 This 
mechanism garnered further support when an in vitro assay with VSG was conducted 
with biotin-LC-hydrazide as the GPI anchor mimic.66 Soluble VSG was pulled-down with 
streptavidin demonstrating biotinylation of the protein product, consistent with VSG 
transamidation. Sulfhydryl alkylating agents inhibited this reaction, providing the first 
evidence of a reactive cysteine and thioester intermediate.66 
It took nearly fifteen years to identify the subunits that comprise GPI-T (the yeast 
subunits are listed in order of their discovery with the human subunits in parentheses): 
Gaa1 (GPAA1), Gpi8 (PIG-K), Gpi16 (PIG-T), Gpi17 (PIG-S), and Gab1 (PIG-U) (Figure 
1.5).8-14 In T. brucei, Gpi17 and Gab1 are replaced with two unrelated subunits, TTA1 
and TTA2.91 Each subunit contains at least one transmembrane (TM) domain that spans 
the ER membrane. T. brucei expresses a soluble form of Gpi8 which lacks its TM 
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domain.92 All five subunits purify as one complex in human cells and the entire complex 
can be co-purified from yeast.13, 93 Conditions have also reported to purify Gpi8, Gaa1, 
and Gpi16, without Gpi17 and Gab1, from yeast.11 
 
Figure 1.5. A cartoon representation of the five subunits of S. cerevisiae GPI-T.13 
Each subunit contains at least one transmembrane domain to localize it to the ER 
membrane. 
 
The membrane-bound nature of GPI-T and the absence of a reliable assay have 
hindered fundamental research on this enzyme. More than a decade after the discovery 
of the fifth and final subunit, Gab1/PIG-U, the subunit stoichiometry and the roles of each 
individual subunit are just beginning to be elucidated.13 GPI anchoring of proteins is 
necessary for normal cell function and has roles in cancer initiation and progression.4 In 
fact, individual GPI-T subunits have been identified as cancer biomarkers, emphasizing 
the need to characterize this complex enzyme.16 In the following sections, the 
identification of each subunit, its intra- and intersubunit interactions, and its elucidated or 
proposed function will be discussed. 
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1.5.1 Identification of the GPI-T subunits 
Gaa1 (GPAA1) was the first GPI-T subunit to be discovered from a mutant, 
temperature-sensitive yeast strain unable to display GPI-APs at the cell surface at 37 
°C.8 Radiolabeling studies with [3H]-inositol in this mutant cell line demonstrated that the 
GPI anchor was synthesized, but was not attached to protein substrates and Gas1 was 
not GPI-anchored. Transformation of a plasmid encoding Gaa1 into the mutant strain 
restored anchoring. Sequence analyses of Gaa1 revealed a ~68 kDa protein predicted 
that it has one N-terminal TM domain, a large soluble domain, and five C-terminal TM 
domains with an ER retention sequence. Two N-linked glycosylation sequons (N-X-S/T, 
where X ≠ Pro) were observed at Asn87 (in the soluble domain) and Asn383 (in a 
predicted cytosolic region). Endoglycosidase H (Endo H) treatment, which hydrolyzes N-
linked glycans, resulted in a shift to a lower molecular weight, demonstrating that Gaa1 
was glycosylated by oligosaccharyl transferase (OST) during translocation into the ER.94 
Endo H digestion of the Asn87Ala mutant did not result in this shift, revealing that Asn87 
is the only N-glycosylation site in Gaa1. Immunofluorescence experiments also 
confirmed that Gaa1 is localized to the ER. 
Gpi8 (PIG-K) was the second subunit of GPI-T identified.9 The gpi8-1 mutant yeast 
cell line was able to synthesize the full-length GPI anchor, but did not display GPI-APs at 
the cell surface. Sequence analyses predicted that Gpi8 is an ~47 kDa protein with an 
N-terminal signal sequence for translocation into the ER, one C-terminal TM domain, 
and three N-glycosylation sites. Localization to the ER was confirmed by Endo H 
digestion and co-fractionation studies. Sequence analyses demonstrated that Gpi8 is 
homologous to a family of cysteine proteases, suggesting that it contains all or some of 
the catalytic active site and catalyzes a transamidase mechanism via a thioester 
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intermediate. Co-immunoprecipitation of GST-Gpi8 with FLAG-Gaa1, provided the first 
evidence of a multi-subunit GPI-T.95 Since eukaryotes including T. brucei and 
Caenorhabditis elegans express a soluble form of Gpi8, the functional importance of its 
TM domain was investgated.92, 95 Expression of Gpi8 lacking its TM domain was 
sufficient for GPI-T activity and its interaction with Gaa1.95 
A search for binding partners of Gpi8 led to the identification of Gpi16. Purification of 
GST-Gpi8 from yeast cells resulted in the co-purification of Gaa1 and Gpi16.11 Native 
polyacrylamide gel electrophoresis (PAGE) visualized two distinct bands for this protein 
complex, migrating between 440 and 660 kDa, suggesting a higher order stoichiometry 
for GPI-T. Analysis of the amino acid sequence for Gpi16 showed signal sequences for 
ER translocation and retention, a C-terminal TM domain, and several N-linked 
glycosylation sites. Similar to Gpi8, ER localization and orientation of Gpi16 towards the 
lumen were confirmed by Endo H digestion and cellular fractionation experiments. 
Deletion of Gpi16 resulted in the accumulation of the GPI anchor and decreased surface 
expression of GPI-APs.  
Tandem affinity purification of FLAG-GST-PIG-K in PIG-K-deficient human cells led 
to the co-isolation of PIG-T and PIG-S (the human orthologs of Gpi16 and Gpi17, 
respectively). PIG-S is an ER-localized protein of ~61 kDa with single N- and C-terminal 
TM domains.12 PIG-S knockout cells accumulated GPI anchor and showed reduced GPI-
AP expression. Both effects were recovered by transfection of a plasmid encoding PIG-
S. Interestingly, in S. cerevisiae, Gpi17 does not form a stable complex with Gpi8, Gaa1, 
and Gpi16.96 Depletion of Gpi17 did not reduce expression of Gpi8, Gaa1, or Gpi16. 
While PIG-S is essential for GPI anchor attachment to proteins in human cells, Gpi17 
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might not be necessary in yeast; the Δgpi17 yeast mutant accumulated the full-length 
GPI anchor, but a lower amount relative to the Δgpi8, Δgaa1, and Δgpi16 mutants.12 
In 2003, the fifth and presumably the final subunit of GPI-T (PIG-U/Gab1) was 
discovered.13 Aerolysin, a bacterial toxin that binds GPI anchors and causes cell lysis, 
was used to identify CHO cells resistant to this toxin and therefore defective in GPI 
anchoring of proteins. Transfection of the cDNA encoding PIG-U, a highly hydrophobic 
protein of ~38 kDa, restored surface expression of the GPI-APs CD59 and DAF in this 
mutant CHO strain; the yeast homolog Gab1 partially restored GPI anchoring of 
proteins. Purification of FLAG-GST-PIG-K resulted in the co-purification of the 
heteropentameric GPI-T complex. These results demonstrate that PIG-U is essential for 
GPI anchoring of proteins and Gab1 is a functional homolog of PIG-U. Similar to Gpi17, 
Gab1 might not associate with Gpi8, Gaa1, and Gpi16 in S. cerevisiae.11 
1.5.2 Functions of the GPI-T subunits 
As noted above, Gpi8, Gaa1, and Gpi16 co-purify as one complex from S. 
cerevisiae, without either Gpi17 or Gab1, at least at detectable limits.11 Native PAGE 
analysis of this purified GPI-T heterotrimer resulted in two bands spanning from ~430 to 
660 kDa, suggesting that more than one copy of each subunit may assemble to form the 
active GPI-T complex. 
Based on Gpi8’s similarity to a family of cysteine proteases, conserved cysteine and 
histidine residues were identified and mutated.15 Cys199Ala and His157Ala mutations 
resulted in the accumulation of the GPI anchor and abolished expression of the GPI-AP 
Gas1. Incubation of trypanosomes with the sulfhydryl alkylating reagents iodoacetamide, 
p-chloromercuribenzoate, and p-chloromercuriphenylsulfonic acid inhibited 
transamidation activity.66 The results from these reports suggest that GPI-T contains a 
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cysteine-histidine catalytic dyad and its mechanism is similar to cysteine proteases 
(Figure 1.6). 
 
Figure 1.6. A proposed mechanism catalyzed for GPI-T-mediated transamidation 
of protein substrates.15 Based on the importance of His157 and Cys199 for GPI-T 
activity, and the evolutionary relationship between Gpi8 and some cysteine proteases, it 
was proposed that GPI-T catalyzes a cysteine protease-like mechanism. His157 would 
deprotonate Cys199 for nucleophilic attack at the ω-site to form a thioester intermediate. 
The GPI anchor substrate would then attack the activated carbonyl to displace Cys199 
and form the GPI-AP. 
 
To simplify expression and biochemical studies with Gpi8, sequence analyses and 
structural predictions revealed that this subunit contains a soluble domain, Gpi823-380, 
divided into two sub-domains; a caspase-like domain and a smaller domain that is not 
similar to any known proteins.97 Overlay of the caspase-like domain model (Gpi823-306) 
with the crystal structure of caspase-1 from Spodoptera frugiperda showed structural 
similarities (Figure 1.7). Caspases are active as homodimers, which led to the 
hypothesis that Gpi823-306 assembles into a homodimer. Expression and purification of 
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GST-Gpi823-306 from Escherichia coli (E. coli) followed by native PAGE analysis and 
matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF 
MS) allowed visualization of the Gpi823-306 homodimer.97 In S. cerevisiae, this Gpi823-306 
homodimer is covalently linked through a disulfide bond and dimerization may be 
promoted by its N-glycans.93 Binding experiments using synthetic propeptides and cross-
linking experiments with miniPLAP that contained the photo-reactive amino acid Nε-(5-
azido-2-nitrobenzoyl)-lysine near its ω-site showed that Gpi8 interacts with the protein 
substrate, but is catalytically inactive, suggesting that one or more of the other GPI-T 
subunits are necessary for transamidase activity.97, 98 
 
Figure 1.7. Predicted structural similarities between S. cerevisiae Gpi823-306 and 
Spodoptera frugiperda caspase-1. a) A Rosetta model of the large, caspase-like 
domain of Gpi823-306 (magenta) is overlaid with the crystal structure of caspase-1 (green, 
PDB: 1M72).97, 99 b) The active site residues from the Rosetta model of Gpi823-306 
(magenta) are overlaid with the catalytic dyad of caspase-1 (green, PDB: 1M72).4, 97, 99 
This figure was obtained from reference 4 with permission from www.tandfonline.com. 
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Using similar prediction methods, the Gaa150-343 open reading frame was constructed 
and co-overexpressed with GST-Gpi823-306 in E. coli.100 GST-Gpi823-306 and His6-Gaa150-
343 were co-purified from this strain using glutathione resin. These two soluble domains 
assemble and co-purify in a complex whose size is most consistent with an α2β2 
stoichiometry. Immunoprecipitation of Gaa150-343-HA from total yeast lysate resulted in 
the co-immunoprecipitation of Gpi823-306-V5-His6.100 These data demonstrate that Gpi823-
306 and Gaa150-343 form a stable and specific complex in yeast in the absence of a soluble 
form of Gpi16. 
Truncation of a conserved face of Gaa150-343 (residues 291-343) did not disrupt its co-
purification with GST-Gpi823-306,100 leading to the hypothesis that this region may 
comprise part of GPI-T’s active site. Sequence analyses and structural predictions of 
Gaa150-343 demonstrate that this subunit is similar to glutaminyl cyclase and zinc-
dependent aminopeptidases, further supporting that Gaa1 may contain part of GPI-T’s 
active site (Figure 1.8), although the metal ligands are not all conserved.100, 101 Photo-
crosslinking experiments with miniPLAP showed that Gaa1 also interacts with the 
proprotein substrate.98 A chimera of GPAA1, where the C-terminal TM domains were 
truncated, was unable to express GPI-APs at the cell surface in vivo.102 Further 
sequence analyses of GPAA1 revealed a conserved proline in its last TM domain.103 
Mutation of a conserved proline in the last TM domain of GPAA1 (Pro609Leu) produced 
a GPAA1 variant that no longer immunoprecipitated with the GPI anchor, suggesting that 
GPAA1 is involved in GPI anchor recognition.103 
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Figure 1.8. Predicted structural models of S. cerevisiae Gaa150-343. The tertiary 
structures of two models of Gaa1 are shown.100 The Gaa150-343 model produced by 
Rosetta (blue) was based on a zinc-dependent aminopeptidase from Aeromonas 
proteolytica (PDB: 1RTQ).104 RaptorX predicted a model (magenta) with similar tertiary 
structure based on the glutaminyl cyclase from Drosophila melanogaster (PDB: 
4F9U).105 The core secondary structures from these two models are highly similar. This 
figure was obtained from reference 100 with permission from Elsevier. 
 
The human and trypanosomal homologs of Gpi8 and Gpi16 interact via a disulfide 
bond, while Gpi823-306 and Gpi1620-550 do not.93, 106 These results further suggest that the 
assembly of an active GPI-T may possess species-specific differences. While the 
function of Gpi16 is unclear, this subunit co-purifies with Gpi8 and Gaa1 and is 
necessary for transamidation.11, 12 Gpi16 may recognize the proprotein substrate, based 
on sequence and structural similarities with prolyl oligopeptidase, though this hypothesis 
has not been investigated experimentally.107 
PIG-S and PIG-U (the human orthologs of Gpi17 and Gab1, respectively) co-purify 
with the other subunits, Gpi8, Gaa1, and Gpi16 can be purified without Gpi16 and 
Gab1.11, 13, 96 Gpi17 does not share homology with any known protein, but is necessary 
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for transamidation in mammalian cells.12 Gab1 has weak sequence similarity to fatty acid 
elongases and may also recognize the GPI anchor.13 
1.5.3 In vitro methods to assay purified GPI-T 
Previous assays developed to characterize GPI-T used cell lysates, crude 
microsomes, or cell-free translation systems.75, 77, 87 These methods require analyses by 
SDS-PAGE and autoradiography to detect processing of a preproprotein substrate to its 
mature GPI-anchored form and/or are unable to quantify GPI-T activity and investigate 
subunit function without other proteins or cellular components that may influence GPI 
anchoring of proteins. A simple, qualitative, in vitro assay was reported in 2002 that uses 
a short, synthetic tetrapeptide substrate with the fluorophore 7-amino-4-methylcoumarin 
(AMC) at its C-terminus (Ac-SVLN-AMC).92 GPI-T-mediated AMC cleavage resulted in 
an increase in AMC fluorescence. This method required an overnight incubation of the 
peptide substrate with trypanosomal lysate or purified T. brucei Gpi8 and time-
dependent results were not reported. The peptide substrates used in this report lack a C-
terminal signal sequence, which is necessary for recognition by GPI-T, and so the utility 
of this assay remains unclear.4 
The research conducted by Dr. Sandamali A. Ekanayaka and other previous 
Hendrickson lab members developed and optimized a peptide cleavage assay using an 
internally quenched peptide substrate with the purified S. cerevisiae GPI-T.108 This assay 
was designed to characterize the activity of the purified GPI-T similar to a method that 
uses an internally quenched peptide to monitor in vitro protease activity.109 A peptide 
substrate based on the wild-type (WT) CD52 sequence was chosen for testing. The 
human CD52 antigen preproprotein is processed to a 37 amino acid proprotein after 
cleavage by the signal peptidase in the ER. It is further truncated and anchored by GPI-
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T to a 12 residue GPI-AP.83, 110 This final peptide is the smallest known GPI-AP, making 
it ideal for an in vitro assay. The sequence of the CD52 propeptide substrate was 
optimized for unique cleavage at the verified WT ω-site83 (Ser12) and to increase its 
solubility. The N-terminus was capped with the fluorophore 2-aminobenzoic acid (Abz, 
λex: 321 nm, λem: 417 nm) and Ile17 was substituted with the quencher 3-nitrotyrosine 
(Y*).109, 111 This fluorophore-quencher pair was selected to measure an increase in 
fluorescence upon cleavage and transamidation of the peptide by the purified soluble 
GPI-T heterotrimer, as depicted in Figure 1.9. 
 
Figure 1.9. A cartoon representation of the assay designed to measure GPI-T 
activity. A peptide substrate was synthesized with the fluorophore 2-aminobenzoic acid 
(Abz, purple circle) and the quencher 3-nitrotyrosine (red circle) flanking the ω-site. An 
increase in fluorescence after the addition of purified GPI-T in the presence of 
hydroxylamine (NH2OH) is an indication of peptide cleavage and transamidation. 
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Dr. Ekanayaka performed assays with 10 mM hydroxylamine or 10 mM hydrazine, 
and compared these assays to control experiments without added nucleophile to 
analyze the nucleophile-dependence of purified GPI-T.108 An increased fluorescence 
signal was observed with hydroxylamine and hydrazine compared to the no nucleophile 
control, consistent with peptide cleavage and transamidation. Purified GPI-T also 
recognized the C-terminal signal sequences of propeptide substrates and exhibited 
specificity at the ω-site, which demonstrates the full-length S. cerevisiae GPI-T retains 
activity in vitro similar to the mammalian enzyme in vivo.75, 81, 82 Unfortunately, efforts to 
identify and characterize the product of this assay were unsuccessful. These results 
reported in Dr. Ekanayaka’s dissertation provide the first method to measure the activity 
of purified GPI-T in a high-throughput, time-dependent manner.108 
1.6 Post-GPI attachment to proteins 
After GPI anchor addition to the protein substrate, GPI-APs undergo several 
modifications to their glycan and lipid moieties.30 While still in the ER, yeast Bst1 and 
human PGAP1 (post-GPI attachment to proteins 1) hydrolyze the acyl chain from the 
inositol ring (Figure 1.10, step 1).112 Next, Ted1/PGAP5 removes the EtNP from Man2 
(Figure 1.10, step 2).113 Removal of each of these modifications is necessary for the 
transport of GPI-APs from the ER to the Golgi apparatus; Δpgap1 and Δpgap5 strains 
were unable to sort GPI-APs to the ER exit sites (ERES).114 Yeast Cdc1 removes the 
EtNP from Man1 (Figure 1.10, step 3), which remains on this mannose in mammalian 
GPI-APs. Removal of this EtNP is necessary for covalent attachment of GPI-APs to the 
yeast cell wall (see section 1.6.2).52 Later lipid remodeling in yeast takes place in the ER, 
while these modifications take place in the Golgi in mammalian cells (discussed in the 
following section).30 
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Precursor GPI anchors are synthesized with acyl chains at the sn-1 and sn-2 
positions of PI.30 Per1 hydrolyzes the unsaturated acyl chain from sn-2 and this position 
of lyso-PI is reacylated with a C26:0 chain by Gup1 in yeast.115, 116 Ceramide can replace 
the acyl chain at the sn-2 position in yeast, a reaction that is catalyzed by Cwh43.117 
 
Figure 1.10. Modifications to glycans of yeast GPI-APs in the ER. A cartoon 
representation of the PGAP modifications that occur on yeast GPI-APs in the ER.30 
Section 1.6 discusses these reactions in further detail. 
 
1.6.1 Trafficking of GPI-APs 
After modification of the GPI anchor in the ER, the p24 protein complex binds GPI-
APs at the ERES.30 Inositol deacylation and removal of the EtNP from Man2 are both 
critical for recognition of the GPI-APs at the ERES in yeast.114 There are four families of 
p24 proteins (p24α, p24β, p24γ, and p24δ), which possess C-terminal cytosolic tails to 
recruit the cytosolic coat protein complex II (COPII).118 COPII recruitment results in 
vesicle formation for transport of GPI-APs to the Golgi apparatus. 
Mammalian GPI-APs undergo lipid remodeling in the Golgi; these reactions are 
catalyzed by enzymes homologous to yeast Per1 and Gup1. PGAP3 removes the 
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unsaturated acyl group from the sn-2 position of the precursor PI to form the lyso-GPI-
AP.119 PGAP2 reacylates lyso-PI with a saturated fatty acid, generally C18:0.120 Further 
modifications to the glycan portion of the GPI anchor, such as sialylation, may take place 
in the Golgi.30 The mechanism for transport of GPI-APs from the Golgi to the plasma 
membrane is unclear. GPI anchor lipid remodeling is required for the localization of GPI-
APs to lipids rafts at the plasma membrane. Δpgap3 Δpgap2 knockout cells that produce 
GPI-APs with an unsaturated fatty acid chain at the sn-2 position of the GPI anchor were 
used to study GPI-AP localization.119 Detergent-resistant membranes were isolated to 
analyze lipid rafts that contain GPI-APs. Reduced levels of GPI-APs were observed in 
the lipid raft fraction. Transfection of the Δpgap3 Δpgap2 cell line with PGAP3 and 
PGAP2 restored localization of GPI-APs, observed by their co-localization with the non-
GPI-anchored lipid raft marker caveolin-1. In the single PGAP2 deletion mutant, GPI-
APs were secreted rather than expressed tethered to the cell surface.120 Consequently, 
the modifications catalyzed by PGAP3 and PGAP2 are necessary for the proper 
localization of GPI-APs. 
1.6.2 Transfer of GPI-APs to the yeast cell wall 
In yeast, certain GPI-APs undergo further modification to become covalently 
attached to the outer glucan layer of the cell wall (Figure 1.11).121 The yeast cell wall is 
composed of β1,6-glucan, β1,3-glucan, and chitin layers. In these cases, the GPI-AP 
and the mannoses of the GPI anchor are transferred to the outermost β1,6-glucan layer, 
displacing the lipid portion of the GPI anchor. The resulting cell wall proteins (CWPs) are 
involved in a variety of essential processes including cell wall biogenesis and stability, 
nutrient uptake, and cell-cell adhesion.121 
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Figure 1.11. Localization of GPI-APs in S. cerevisiae.121 A cartoon representation 
showing the non-covalent interaction of a GPI-AP at the plasma membrane versus its 
covalent attachment to the outer glucan layer of the cell wall. Glycoprotein transfer from 
the plasma membrane to the cell wall may be catalyzed by Dcw1 and Dfg5.122 
 
Two GPI-APs in S. cerevisiae, Dcw1 and Dfg5, are proposed to have roles in 
glycoprotein transfer from the plasma membrane to the cell wall.122 These proteins share 
54% amino acid identity with one another and are homologous to a bacterial α1,6-
mannosidase. The Δdcw1 Δdfg5 double mutant was lethal to S. cerevisiae. The single 
mutant strains led to increased secretion rather than cell wall attachment of the cell wall 
protein Cwp1.52 Experiments investigating the activities of Dcw1 and Dfg5 or their 
proposed interactions with GPI-APs have not been reported. 
1.7 GPI-APs play various roles in cellular processes and pathogenesis 
Many GPI-APs are necessary for normal cell function, but their overexpression 
occurs in many cancers and other pathophysiological pathways.4 In this section, various 
roles that GPI-APs and GPI-T play in development and disease will be highlighted. 
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Mammalian GPI-APs have roles in processes as early as fertilization and 
development.6, 123 Fusion between sperm and egg is dependent on the interaction 
between proteins expressed on the surface of these cells, some of which are GPI-APs. 
IZUMO1, a membrane protein on the surface of sperm, binds the recently discovered 
GPI-anchored IZUMO1 receptor (IZUMO1R or Juno).124 Juno’s localization was 
confirmed by fluorescence microscopy and GPI anchoring was demonstrated by 
treatment with PI-PLC. Female mice lacking Juno were infertile and Juno-deficient eggs 
were unable to fuse with sperm. Neural GPI-APs such as the neural cell adhesion 
molecule (NCAM) 120 isoform promotes cell-cell contact and is involved in tissue 
development.2 Juno and NCAM only briefly highlight two of the fundamental roles GPI-
APs play. 
GPI-APs are involved in a wide range of cancers (described in the following section), 
prion aggregation, and parasitic infection.4 T. brucei infects mammals through tsetse flies 
and causes sleeping sickness. The surface of T. brucei may express up to 107 copies of 
a single VSG and individual parasites express different variants, which allows these 
protozoa to evade the mammalian host immune system.5 Also, two GPI-APs expressed 
in P. falciparum, merozoite surface protein 1 and 2 (MSP-1 and MSP-2) that comprise 
approximately two-thirds of this parasite’s surface are attractive targets for malaria 
therapeutics.125 
1.8 GPI-T’s roles in cancer 
Shortly after the identification of the fifth subunit, Gab1, the gene for the human 
ortholog (PIGU) was reported as a bladder cancer oncogene.126 Increased levels of the 
PIG-U subunit was observed in approximately one-third of bladder cancer cell samples 
compared to healthy tissues and injection of PIG-U-expressing cells into mice induced 
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tumor growth. PIG-U overexpression in cultured cells also led to increased surface 
expression of GPI-uPAR, a well-known oncogene. This observation provided the first link 
between increased GPI-T subunit expression and cancer. Since this report, aberrant 
expression of each GPI-T subunit has been observed in a myriad of cancers (Table 
1.2).16 It is generally unclear how changes in subunit expression affect GPI-T activity and 
are related to cancer initiation and metastasis. 
Table 1.2. Example of subunit expression changes in various cancers. ↑ and ↓ 
represent protein overexpression and underexpression, respectively, in cancer cells 
compared to healthy cells.4, 16 
 
Cancer 
type 
PIG-T PIG-K GPAA1 PIG-S PIG-U 
Bladder - ↓ - - ↑ 
Breast ↑ ↑ - ↑ ↑ 
Colon ↑ ↓ - - - 
Lung ↑ - ↑ ↑ ↑ 
Prostate - - ↑ - ↑ 
 
One link between GPI-T and cancer is that subunit overexpression leads to 
increased levels of GPI-APs involved in signaling pathways. e.g. in bladder cancer cells 
overexpressing PIG-U, an increase in GPI-APs, including uPAR, was observed.126 
Increased surface expression of uPAR led to the phosphorylation and thus the activation 
of the transcription factor STAT-3, which is known to induce overexpression of tumor 
suppressor genes and promote cancer proliferation through inflammatory responses. 
Interestingly, PIG-K, which contains most or all of GPI-T’s active site, was 
underexpressed in bladder and colon cancer cells, suggesting that a decrease in GPI-
AP levels may also affect normal cellular processes leading to cancer initiation.15, 16 
Expression of several proteins involved in cancer cell invasion were observed in 
cancer cells that overexpress GPAA1 and PIG-T.127 In the highly invasive MDA157, 
MDA231, and MDA436 breast cancer cell lines, phosphorylation and activation of 
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paxillin, which is not GPI-anchored but is involved in tumor growth, was increased. 
Silencing PIGT or GPAA1 reduced levels of paxillin. Overexpression of the transcription 
factor FOXC2, which promotes cell growth, was also observed with the overexpression 
of GPAA1 or PIG-T.128 The mechanisms that connect GPI-T subunit expression levels to 
paxillin are not known. 
Treatment of several cancer cell lines with cigarette smoke extract led to increased 
levels of PIG-U, PIG-T, and GPAA1.129 Interestingly, in cells overexpressing GPAA1, this 
subunit interacted with the epidermal growth factor receptor (EGFR). This GPAA1:EGFR 
association led to phosphorylation of PIG-T and PIG-U by EGFR tyrosine kinase, and 
downstream phosphorylation and activation of paxillin. These results suggest that 
individual GPI-T subunits may recruit proteins, such as EGFR, to the GPI-T complex or 
GPI-T subunits may dissociate and interact with other proteins, activating signaling 
pathways (e.g. paxillin signaling) and leading to cancer metastasis. Elucidation of GPI-
T’s role in cancer initiation and proliferation could lead to new targets for personalized 
cancer therapies. 
1.9 GPI-T’s roles in congenital disorders 
Paroxysmal nocturnal hemoglobinuria (PNH) is a genetic blood disorder that causes 
the excessive breakdown of red blood cells (RBCs).130 Decreased expression of GPI-
anchored CD55/DAF and CD59 are hallmarks of PNH. DAF and CD59 protect cells from 
the host’s immune system and lysis. The absence of these GPI-APs leaves RBCs 
vulnerable to destruction. It is clear that PNH typically results from a mutation in the 
PIGA gene, which encodes for PIG-A, an enzyme involved in the biogenesis of the GPI 
anchor (section 1.3.1).131 Novel mutations have also been discovered in a patient with a 
wild-type PIGA gene, but decreased expression of DAF and CD59. In this case, a 
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heterozygous splice site in the PIGT gene in germline cells and an 8 MB deletion in 
somatic cells caused PNH.132 These data demonstrate that mutations present in genes 
other than PIGA disrupt GPI anchoring of proteins and cause PNH. 
In recent years, mutations in the GPAA1 and PIGT genes have been identified and 
associated with developmental disorders. Individuals with a splicing mutation in GPAA1, 
that caused decreased GPAA1 mRNA and protein levels, exhibited cerebellar atrophy 
and osteopenia.133 Several mutations in the PIGT gene have been reported in patients 
that displayed congenital defects including muscle hypotonia and brain atrophy.134, 135 
These findings highlight the necessity of GPAA1 and PIG-T, and the complex roles GPI-
T play in development. 
1.10 Dissertation research summary 
This dissertation research describes progress towards the characterization of the 
subunit organization and activity of the S. cerevisiae GPI-T. We hypothesize that Gpi8, 
Gaa1, and Gpi16 assembles and forms a core GPI-T heterotrimer in S. cerevisiae since 
these subunits can be purified without Gpi17 and Gab1.11 To simplify investigating GPI-
T, the soluble domains of Gpi8, Gaa1, and Gpi16 were constructed and expressed with 
various affinity tags for protein-protein interaction studies and transamidation activity 
assays. 
Chapter 2 describes the characterization of the protein-protein interactions between 
the S. cerevisiae soluble GPI-T heterotrimer subunits. Co-immunoprecipitation and co-
purification experiments were performed and demonstrate that each individual soluble 
heterodimer assembles into a stable complex without a requirement for the third soluble 
domain. Furthermore, the soluble GPI-T heterotrimer assembles and co-purifies as one 
complex without its TM domains. 
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Chapter 2 also discusses the use of the in vitro assay designed and optimized by Dr. 
Ekanayaka to robustly measure the activity of purified GPI-T.108 This assay correlates 
changes in fluorescence, which arise upon cleavage of an internally quenched peptide 
substrate, to GPI-T activity. Activity assays demonstrate that the soluble GPI-T 
heterotrimer retains transamidation activity in vitro. High-performance liquid 
chromatography (HPLC) and electrospray ionization mass spectrometry (ESI-MS) 
methods were designed and optimized with synthetic peptide standards to analyze crude 
assay mixtures. Experiments were also performed to analyze recognition and cleavage 
of propeptide substrates by the purified soluble GPI-T heterotrimer. 
Chapter 3 summarizes this dissertation research and proposes future directions. 
GPI-T assembly, substrate recognition, and the impact of an assay to measure purified 
GPI-T activity are discussed. 
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CHAPTER 2 CHARACTERIZATION OF THE SOLUBLE, MINIMALISTIC 
SACCHAROMYCES CEREVISIAE GPI-T 
 
2.1 Introduction 
GPI anchoring of proteins is a complex post-translational modification. It is predicted 
that ~0.5% of all eukaryotic proteins are modified at their C-termini with a GPI glycolipid 
anchor to become non-covalently associated with the plasma membrane.1, 121 GPI-APs 
play important roles in cell adhesion and development, signaling pathways, regulation of 
the complement system, and other fundamental cellular processes.2, 123 Human GPI-
APs, such as uPAR and the folate receptor, have been recognized as attractive cancer 
biomarkers;4 and many protozoan GPI-APs protect the parasite from the host’s immune 
system, including the VSG expressed in T. brucei.5 GPI-T is a membrane-bound, multi-
subunit enzyme that catalyzes GPI anchor attachment to newly synthesized protein 
substrates in the ER.136 The complexity of GPI-T has hindered fundamental research on 
its subunit assembly and function, which has further limited studies on this enzyme’s role 
in cancer initiation and metastasis. Aberrant expression of different GPI-T subunits has 
been identified in many human cancers (Table 1.2).16, 126-128 GPI anchoring of proteins is 
an essential process,4 but the individual function of each subunit and GPI-T’s roles in 
tumorigenesis remain poorly understood. 
There are five known subunits that assemble to form the S. cerevisiae GPI-T (Figure 
2.1a): Gpi8, Gaa1, Gpi16, Gpi17, and Gab1; the corresponding human subunits are 
PIG-K, GPAA1, PIG-T, PIG-S, and PIG-U, respectively.8-10, 12-14 All five subunits co-purify 
as one complex from both human and yeast cells.13, 93 The Gpi8:Gaa1:Gpi16 GPI-T 
heterotrimer can also be purified from yeast in the absence of Gpi17 and Gab1.11 Gpi8, 
the catalytic subunit, has one C-terminal TM domain and two predicted soluble domains, 
the larger of which has sequence and predicted structural similarity to caspases.9, 15 
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Interestingly, some eukaryotes, including T. brucei, Caenorhabditis elegans, and 
Drosophila melanogaster (D. melanogaster), express a truncated, soluble form of Gpi8, 
which lacks its C-terminal TM domain (T. brucei Gpi8 is 299 residues after its 
translocation into the ER).92, 106 Sequence analyses and structural models suggest the 
soluble domain of Gaa1 is similar to zinc-dependent aminopeptidases and may complete 
GPI-T’s active site.100, 101 This domain is N-terminally flanked by a single TM domain, 
with five additional TM domains on its C-terminal side. Gpi16 contains a single, C-
terminal TM domain, and may be necessary for protein substrate recognition.107 Gab1 
contains a very small soluble domain and an indeterminate number of C-terminal TM 
domains (between eight and ten). Gab1 has some sequence homology with fatty acid 
elongases and may interact with the lipid portion of the GPI anchor. The large soluble 
domain of Gpi17 is flanked by single N- and C-terminal TM domains; its function remains 
unknown.13 
 
Figure 2.1. Cartoon representations of S. cerevisiae GPI-T. a) The five subunits of 
GPI-T are depicted as a cartoon. Each subunit contains at least one transmembrane 
domain embedded in the endoplasmic reticulum membrane. The putative “core” GPI-T 
heterotrimer, composed of Gpi8, Gaa1, and Gpi16, can be purified as one complex from 
yeast.22 The remaining subunits, Gpi17 and Gab1, interact with each other and the 
heterotrimer under specific conditions.19, 20, 28 b) A cartoon representation of the soluble 
domains of the GPI-T heterotrimer studied herein; the expected open reading frames 
after cleavage of the N-terminal ER signal sequences are listed. 
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GPI-T recognizes and cleaves a C-terminal signal sequence in the precursor 
proprotein substrate between the ω-site residue (which becomes the C-terminal residue 
of the mature GPI-AP) and ω+1, the next residue on the C-terminal side of the scissile 
bond.4, 81 This signal sequence is replaced with the GPI anchor, which possesses a core 
structure composed of a phosphatidylinositol moiety, one glucosamine, three mannoses, 
and an ethanolamine phosphate on the third mannose for attachment to the protein 
substrate.4 While GPI anchor attachment is clear, an understanding of the functions and 
arrangement of GPI-T’s subunits has been slow to emerge, with the active site Gpi8 
subunit being the best characterized.15, 93, 97, 100 The larger, soluble domain of S. 
cerevisiae Gpi8 (Gpi823-306) assembles into a caspase-like homodimer, covalently 
bonded through a disulfide bond,93, 97 and contains a conserved Cys-His dyad (Cys199 
and His157) that likely comprises most of GPI-T’s catalytic machinery.9, 15 Similar to a 
cysteine protease, Cys199 presumably forms a thioester intermediate at the α-carbonyl 
of the ω-site residue in the proprotein, displacing the C-terminal signal sequence.66 The 
GPI anchor acts as the nucleophile that reacts with the thioester, forming a new amide 
bond between the ethanolamine phosphate of the GPI anchor and the activated C-
terminus of the protein substrate. His157 acts as a catalytic base and an acid throughout 
this process. In vitro, GPI-T will accept potent nucleophiles such as hydroxylamine or 
hydrazine in place of the GPI anchor.65 It remains unclear how GPI-T recognizes its 
substrates, particularly given that the C-terminal signal sequence in its substrates lack 
any sequence homology and instead contain only a pattern of size, hydrophilicity, and 
hydrophobicity.4 
The large soluble domain of Gpi8, Gpi823-306, is capable of binding synthetic peptide 
substrates in vitro, but is catalytically inactive,97 suggesting that one or more of GPI-T’s 
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other subunits is necessary for thioester formation and transamidase activity. Gpi823-306 
and Gaa150-343 (the soluble domain of Gaa1) also form a stable, higher-order complex 
consistent with an α2β2 stoichiometry.100 A conserved region of Gaa150-343 may contain 
part of GPI-T’s active site since truncation did not disrupt co-purification of Gaa150-343 
with Gpi823-306.100 Although Gpi16’s function is unclear, human PIG-K (Gpi8) and PIG-T 
(Gpi16) are connected via a disulfide bond and S. cerevisiae Gaa1, Gpi8, and Gpi16 can 
be co-purified as a complex without Gpi17 and Gab1.11, 106 These data suggest that the 
Gpi8:Gaa1:Gpi16 heterotrimer may comprise the catalytic core of GPI-T. 
GPI membrane anchoring of proteins was discovered in the 1980s and up to 20% of 
membrane-associated proteins are modified by GPI-T.1 Arguably, this process remains 
the least well understood of any of the common protein modification reactions because 
of two major challenges: the lack of stable overexpression and purification of GPI-T in 
any form and of a reliable assay for this modification reaction. Here a resolution to both 
of these challenges is reported. To simplify protein expression, purification, and subunit-
subunit interaction studies, we focused on the soluble domains of Gpi823-306, Gaa150-343, 
and Gpi1620-551 (Figure 2.1b). We demonstrate that each domain pair (Gpi823-306:Gaa150-
343, Gpi823-306:Gpi1620-551, and Gaa150-343:Gpi1620-551) assemble into stable, heterodimers 
in vivo without a need for the third subunit. Additionally, the three soluble domains 
(Gpi823-306:Gaa150-343:Gpi1620-551) purify together as one complex. We also demonstrate 
that the truncated, soluble GPI-T heterotrimer is catalytically active. These studies 
provide a new chemical tool for further in vitro characterization of GPI-T and important 
insight into the organization of this central, post-translational protein-modifying enzyme. 
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2.2 Results 
2.2.1 Overexpression and purification of the soluble domains of S. cerevisiae 
Gpi8, Gaa1, and Gpi16 
We have previously reported the design, structure prediction, and characterization of 
simplified, truncated forms of Gpi8, glutathione-S-transferase tagged Gpi823-306 (GST-
Gpi823-306),97 and Gaa1 (His6-Gaa150-343).100 These two soluble domains assemble into a 
higher order, heterodimeric complex that is most consistent with an α2β2 stoichiometry.100 
Here, we set out to map the subunit interactions between all three of the core, soluble 
domains of GPI-T, namely Gpi823-306, Gaa150-343, and Gpi1620-551. Several different 
constructs were prepared to facilitate immunoprecipitation studies using these subunits 
(Table 2.1). These plasmids were designed for overexpression in yeast with appropriate 
N-terminal signal sequences for translocation into the ER. Native signal sequences were 
used for Gpi8 and Gpi16 because the soluble domains of these two subunits begin at 
the site of signal sequence processing. Gpi1620-551-V5-His6 was overexpressed in yeast 
and affinity purified using Ni2+-NTA resin (Figure 2.2), demonstrating stable 
overexpression of this domain for the first time. To verify that Gpi1620-551-V5-His6 was 
glycosylated upon translocation into the ER, this purified soluble domain was treated 
with endoglycosidase Hf (Endo Hf) to hydrolyze any N-linked glycans.137 Deglycosylated 
Gpi1620-551-V5-His6 migrated at a lower molecular weight, as expected due to glycan 
removal. The large soluble domain of Gaa1 is separated from its signal sequence by a 
TM domain so our Gaa1 constructs incorporated the signal sequence from 
carboxypeptidase Y (CPY) immediately prior to the start of the predicted soluble 
domain.100 
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Table 2.1. Constructs designed to express the soluble domains of Gpi8, Gaa1, and 
Gpi16. Each construct used to overexpress Gpi823-306, Gaa150-343, and Gpi1620-551 in S. 
cerevisiae is listed with the selection marker, the N-terminal signal sequence for 
translocation into the ER, and the recombinant protein overexpressed after processing 
by the signal peptidase. 
 
Subunit Selection marker 
Predicted N-terminal 
sequence 
Expressed protein 
after N-terminal 
signal sequence 
processing 
Molecular 
weight of the 
expressed 
protein 
Gpi8 URA3 Native (Gpi81-22) Gpi823-306-V5-His6 ~37 kDa 
Gaa1 LEU2 
Carboxypeptidase Y 
(CPY1-20) 
Gaa150-343-TAP ~69 kDa 
Gpi16 URA3 Native (Gpi161-19) Gpi1620-551-V5-His6 ~64 kDa 
Gpi16 TRP1 Native (Gpi161-19) Gpi1620-551-HA ~63 kDa 
Gpi16 LEU2 Native (Gpi161-19) Gpi1620-551-TAP ~95 kDa 
 
 
Figure 2.2. Purification of Gpi1620-551-V5-His6 by Ni2+-NTA resin. Gpi1620-551-V5-His6 
was overexpressed in S. cerevisiae and affinity purified by Ni2+-NTA resin. The elution 
fraction (lane 1) was also treated with endoglycosidase Hf (Endo Hf) to demonstrate the 
presence of N-linked glycosylation (lane 2). These fractions were separated on a 10% 
SDS-PAGE gel and visualized by an anti-V5 Western blot. 
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2.2.2 Three soluble subunits of GPI-T (Gpi823-306, Gaa150-343, and Gpi1620-551) 
assemble into their corresponding heterodimeric pairs in vivo, without a 
requirement for the third subunit 
To expand our understanding of GPI-T subunit associations, we asked whether or 
not Gpi1620-551 stably interacts with either Gpi823-306 or Gaa150-343, without a requirement 
for the third subunit. Gpi8-V5-His6 and Gpi1620-551-HA were co-expressed in yeast and 
clarified total cell lysate was incubated with anti-HA antibodies to immunoprecipitate 
Gpi1620-551-HA; Gpi823-306-V5-His6 was successfully co-immunoprecipitated (Figure 2.3). 
Gpi823-306-V5-His6 did not immunoprecipitate with HA antibodies in the absence of 
Gpi1620-551-HA (Figure A.1). The human orthologs of Gpi8 and Gpi16, PIG-K and PIG-T 
respectively, are covalently associated with one another via a disulfide bond.106 
However, a recent report showed that a disulfide bond does not form between the 
soluble domains of Gpi8 and Gpi16 in yeast.93 Gpi161-551 was also constructed with a C-
terminal tandem affinity purification (TAP)138 tag and its interactions with Gpi823-306-V5-
His6 and Gpi1620-551-TAP were reexamined in the presence of 1 mM dithiothreitol (DTT). 
This switch was made to allow calmodulin purification since DTT would reduce the 
disulfide bond between the heavy and light chains of the HA antibodies and disrupt 
subunit immunoprecipitation. Calmodulin-sepharose purification of Gpi1620-551-TAP also 
resulted in the co-purification of Gpi8-V5-His6 (Figure A.2). These results support a 
specific, noncovalent interaction between the soluble domains of S. cerevisiae Gpi8 and 
Gpi16 without a requirement for overexpression of Gaa1 or a disulfide bond. 
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Figure 2.3. Gpi1620-551-HA separately interacts with Gpi823-306-V5-His6. Co-
immunoprecipitation experiments were conducted as indicated using clarified S. 
cerevisiae lysate (Input) to analyze the protein-protein interactions shown in the cartoon 
schematic at the top of this figure. The Western blots were transferred from SDS-PAGE 
gels run in parallel with the same samples. IP: Antibody used for immunoprecipitation. U: 
Unbound fraction after IP. E: Elution fraction. Top: The presence of Gpi1620-551-HA in the 
eluant from the immunoprecipitation was confirmed by anti-HA Western blot. Bottom: 
The co-immunoprecipiation of Gpi823-306-V5-His6 with Gpi1620-551-HA was confirmed by 
anti-V5 Western blot. The three visible glycoforms of Gpi823-306-V5-His6 are indicated 
with a bracket. Asterisks are placed next to each immunoprecipitated subunit. Full-length 
images of each Western blot are provided in Figure A.4. 
 
 
 
When Gaa150-343-TAP and Gpi1620-551-V5-His6 were co-expressed in yeast, 
immunoprecipitation of Gaa150-343-TAP with IgG sepharose resulted in the co-
immunoprecipitation of Gpi1620-551-V5-His6 (Figure 2.4). To confirm that co-
immunoprecipitation of Gpi1620-551-V5-His6 was due to its specific interaction with Gaa150-
343-TAP, a control immunoprecipitation was performed with total cell lysate from yeast 
overexpressing Gpi1620-551-V5-His6 alone. The soluble domain of Gpi16 did not 
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immunoprecipitate with IgG (Figure A.3). These results demonstrate that the soluble 
domains of Gaa1 and Gpi16 form a stable heterodimer without a requirement for Gpi8.  
 
Figure 2.4. Gpi1620-551-V5-His6 separately interacts with Gaa150-343-TAP. Co-
immunoprecipitation experiments were conducted as indicated using clarified S. 
cerevisiae lysate (Input) to analyze the protein-protein interactions shown in the cartoon 
schematic at the top of this figure. The Western blots were transferred from SDS-PAGE 
gels run in parallel with the same samples. IP: Antibody used for immunoprecipitation. U: 
Unbound fraction after IP. E: Elution fraction. Top: The presence of Gaa150-343-TAP in 
the eluant from immunoprecipitation was confirmed by anti-Protein A Western blot. 
Bottom: Co-immunoprecipication of Gpi1620-551-V5-His6 with Gaa150-343-TAP was 
demonstrated by anti-V5 Western blot. Full-length images of each Western blot are 
provided in Figure A.5. 
 
Altogether, the data shown in Figures 2.2-2.4, coupled with our previous 
demonstration that Gpi823-306 and Gaa150-343 assemble into a heterotetramer,100 show 
that the soluble domains of Gpi8, Gpi16, and Gaa1 are highly interconnected, with 
significant contacts forming between each pair of subunits. Given that overexpression of 
individual GPI-T subunits occurs in certain cancers,16 these results suggest that sub-
populations of heterodimeric complexes might assemble to cause alterations in GPI-T 
activity. 
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2.2.3 The soluble, truncated GPI-T heterotrimer assembles and purifies as one 
complex 
Full-length Gpi8, Gaa1, and Gpi16 can be co-purified from the ER membrane as one 
complex from yeast, with93 or without Gpi17 and Gab1.11, 96 To determine whether this 
soluble GPI-T heterotrimer, composed of Gpi823-306, Gaa150-343 and Gpi1620-551 (Figure 
2.5a), could be assembled in vivo and purified, Gpi823-306-V5-His6, Gaa150-343-TAP, and 
Gpi1620-551-HA were co-expressed in yeast. The clarified total cell lysate was incubated 
with calmodulin-sepharose to gently purify Gaa150-343-TAP (Figure 2.5b, top panel, anti-
Protein A Western blot). This purification resulted in the co-purification of both Gpi8-V5-
His6 (Figure 2.5b, middle panel, anti-V5 Western blot) and Gpi1620-551-HA (Figure 2.5b, 
bottom panel, anti-HA Western blot). This result is the first demonstration that the 
soluble GPI-T heterotrimer can assemble into a complex without a need for TM domains. 
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Figure 2.5. Gpi823-306-V5-His6, Gaa150-343-TAP, and Gpi1620-551-HA assemble into and 
purify as a single, heterotrimeric complex. a) A cartoon representation of the co-
purified Gpi823-306-V5-His6:Gaa150-343-TAP:Gpi1620-551-HA soluble GPI-T heterotrimer. b) 
Purification of Gaa150-343-TAP from S. cerevisiae cell lysate results in the simultaneous 
co-purification of both Gpi823-306-V5-His6 and Gpi1620-551-HA. These subunits were 
visualized in the eluant by anti-Protein A (top panel), anti-V5 (middle panel), and anti-HA 
(bottom panel) Western blots. Samples were also treated with endoglycosidase Hf to 
remove any glycosylation for comparison. Input: Clarified supernatant after lysis. U: 
Unbound fraction. E: Elution fraction. The Western blots shown in each of the panels 
were transferred from three SDS-PAGE gels performed in parallel with the same 
samples. Complete images of the three Western blots are provided in Figure A.6. 
 
To verify that each subunit was glycosylated upon translocation into the ER, the 
purified soluble GPI-T heterotrimer was treated with Endo Hf to hydrolyze any N-linked 
glycans.137 Each of these core GPI-T soluble subunits contains at least one N-X-S/T N-
linked glycosylation sequon.94 Gpi823-306-V5-His6 may be glycosylated at Asn23 and 
Asn256. Unglycosylated, mono- and di-glycosylated forms of Gpi823-306-V5-His6 were 
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observed by anti-V5 Western blot (Figure 2.5b, middle panel, lane 3). Gaa150-343 has an 
N-glycosylation site at Asn87, and Gpi1620-551 may be glycosylated at Asn29, Asn184, 
Asn205, and/or Asn419. Both Gaa150-343-TAP and Gpi1620-551-HA migrated as one band 
at a molecular weight higher than expected (Figure 2.5b, lane 3 in the top and bottom 
panels, respectively). In all three cases, the deglycosylated subunits migrated at lower 
molecular weights, as anticipated due to glycan removal (Figure 2.5b, lane 4 in each 
panel). 
2.2.4 The soluble GPI-T heterotrimer retains activity in vitro 
With our purification of the soluble heterotrimer of GPI-T (Figure 2.5b), we next set 
out to determine whether this complex retained catalytic activity. Such a demonstration 
would show that truncation of these subunits did not disrupt the overall GPI-T structure 
and activity, opening up an array of experimental possibilities to further understand this 
complicated enzyme. The in vitro peptide cleavage assay discussed in section 1.5.3, 
developed and optimized by Dr. Ekanayaka, was used to analyze whether the soluble 
GPI-T heterotrimer retained transamidase activity.108 
This assay was designed to characterize the activity of the purified soluble GPI-T 
heterotrimer similar to a method that uses an internally quenched peptide to monitor in 
vitro protease activity.109 A peptide substrate based on the wild-type (WT) CD52 
sequence was chosen for testing (Table 2.2). The human CD52 antigen preproprotein is 
processed to a 37 amino acid proprotein after cleavage by the signal peptidase in the 
ER. It is further truncated and anchored by GPI-T to a 12 residue GPI-AP.83, 110 This final 
peptide is the smallest known GPI-AP, making it ideal for an in vitro assay. The 
sequence of the CD52 propeptide substrate was optimized for unique cleavage at the 
verified WT ω-site83 (Ser12) and to increase its solubility (Abz-37mer, Table 2.2). The N-
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terminus was capped with the fluorophore 2-aminobenzoic acid (Abz, λex: 321 nm, λem: 
417 nm) and Ile17 was substituted with the quencher 3-nitrotyrosine (Y*).109, 111 This 
fluorophore-quencher pair was selected to measure an increase in fluorescence upon 
cleavage and transamidation of the peptide by the purified soluble GPI-T heterotrimer, 
as depicted in Figure 2.6. Synthesis of this Abz-37mer required double to triple coupling 
reactions, presumably due to the hydrophobicity of the first 25 amino acids. The 
synthesis was monitored after the addition of every 2-5 amino acids by reversed-phase 
HPLC (RP-HPLC) and ESI-MS. The final peptide required HPLC purification but was 
obtained to near homogeneity. Its identity was confirmed by mass spectrometry. 
Table 2.2. Sequences of the Abz-37mer peptides and wild-type CD52. Abz: 2-
aminobenzoic acid, Y*: 3-nitrotyrosine. 
 
Peptide N-terminus 
N-terminal 
sequence 
ω-
site C-terminal signal sequence 
WT CD52 H3N+ GQNDTSETSSP S ASSNISGGIFLFFVANAIIHLFCFS 
Abz-37mer Abz GQKDTSEKSSP S ASKNY*SGGIFLFFVANAIIHLFHFS 
D4 Abz GQKDTSEKSSP S ASKNY*SGGIFLFFVANAIIHL 
D8 Abz GQKDTSEKSSP S ASKNY*SGGIFLFFVANA 
D19 Abz GQKDTSEKSSP S ASKNY*S 
S12D Abz GQKDTSEKSSP D ASKNY*SGGIFLFFVANAIIHLFHFS 
S12R Abz GQKDTSEKSSP R ASKNY*SGGIFLFFVANAIIHLFHFS 
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Figure 2.6. A cartoon representation of the assay designed to measure GPI-T 
activity. A peptide substrate was synthesized with the fluorophore 2-aminobenzoic acid 
(Abz, purple circle) and the quencher 3-nitrotyrosine (red circle) flanking the ω-site. An 
increase in fluorescence after the addition of purified soluble GPI-T heterotrimer in the 
presence of hydroxylamine (NH2OH) is an indication of peptide cleavage and 
transamidation. 
 
The Abz-37mer peptide was incubated in assay buffer with 1 µM purified soluble 
heterotrimer in the presence versus absence of 10 mM hydroxylamine and its 
fluorescence emission at 417 nm was recorded over time. An increased rate of 
fluorescence was observed for the assay with hydroxylamine compared to the reaction 
without hydroxylamine (Figure 2.7a and Table 2.3), consistent with GPI-T-mediated 
cleavage and transamidation of the Abz-37mer. The fluorescence response was 
biphasic in nature, which may be due to distinct rates from peptide substrate binding and 
thioester formation (Table 2.3, rate 1, Abz-37mer peptide + NH2OH, initial slope, 4.20 ± 
0.53 AU/min) and transamidation of the intermediate (Table 2.3, rate 2, Abz-37mer 
peptide + NH2OH, second slope 1.49 ± 0.12 AU/min). These results suggest that 
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transamidation of the thioester is rate limiting with hydroxylamine, perhaps because the 
active site of the enzyme is in a closed conformation. The fluorescence signal began to 
plateau ~1 h after initiating the assay, suggesting that the soluble heterotrimer is 
unstable over time.  
 
Figure 2.7. The purified soluble GPI-T heterotrimer is catalytically active in vitro. a) 
Traces of assays using the Abz-37mer peptide with and without 10 mM NH2OH after the 
addition of 1 µM purified soluble heterotrimer compared to a no enzyme control. 
Fluorescence was recorded for 10 min. b) HPLC analysis of the 1 h assay with 10 mM 
NH2OH (blue) overlaid with the Abz-12mer hydroxamic acid synthetic standard (maroon) 
and the no enzyme negative control (black). c) ESI-MS analysis of the Abz-12mer 
hydroxamic acid product. Exact mass = 1384 g/mol. Observed (m+2H+)2+ = 693 m/z. 
Calculated (m+2H+)2+ = 693 m/z. 
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Table 2.3. Rates observed with the soluble heterotrimer. *Relative rates are given 
with respect to the rates observed with the Abz-37mer peptide and NH2OH. **AU = 
Arbitrary fluorescence units. 
 
Peptide Initial slope (∆AU/min**) 
Relative 
rate* 
Second slope 
(∆AU/min) 
Relative 
rate* 
Abz-37mer + NH2OH 4.20 ± 0.53 1 1.49 ± 0.12 1 
Abz-37mer - NH2OH 1.78 ± 0.58 0.56 0.77 ± 0.30 0.52 
Abz-37mer - enzyme -0.09 ± 0.30 0 0.04 ± 0.06 0.03 
D4 + NH2OH 3.51 ± 0.40 0.83 0.82 ± 0.26 0.55 
D8 + NH2OH 1.92 ± 0.37 0.46 0.81 ± 0.68 0.54 
D19 + NH2OH 0.33 ± 0.50 0.08 -0.14 ± 0.13 0 
S12D + NH2OH 2.60 ± 0.23 0.62 0.95 ± 0.18 0.64 
S12R + NH2OH 0.48 ± 0.59 0.11 0.39 ± 0.17 0.26 
 
A crude assay mixture was analyzed by RP-HPLC and ESI-MS. A synthetic Abz-
12mer hydroxamic acid peptide was prepared and analyzed for comparison. The peak 
intensity corresponding to starting peptide decreased and the expected Abz-12mer 
hydroxamic acid product eluted in one peak (Figure 2.7b, blue trace) and was confirmed 
by ESI-MS (Figure 2.7c). The peptide product eluted at the same time as the Abz-12mer 
hydroxamic acid synthetic standard (Figure 2.7b, maroon trace). The synthetic peptide 
standard elutes as two peaks, which are expected to be epimers. To our knowledge, 
these results represent the first time that both robust, time-dependent GPI-T activity has 
been measured and transamidation of a propeptide substrate has been observed in 
vitro. 
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2.2.5 The soluble GPI-T heterotrimer recognizes the propeptide’s C-terminal signal 
sequence 
In vivo, the C-terminal signal sequence of a GPI-T proprotein substrate is recognized 
by the enzyme, cleaved, and replaced with the GPI anchor.4 Truncation of the 
hydrophobic region from the C-terminal signal sequence of the mammalian GPI-AP DAF 
resulted in secretion rather than GPI-anchoring of this protein.81 To investigate substrate 
recognition by the soluble GPI-T heterotrimer, C-terminally truncated versions of the 
Abz-37mer peptide were synthesized and assayed (Table 2.2). The Δ4 and Δ8 peptides 
proved to be substrates for the soluble, heterotrimeric GPI-T, with initial rates that are 
reduced by 17 and 54% respectively, relative to the Abz-37mer peptide (Figure 2.8, 
Table 2.3). Surprisingly, the Δ19 peptide was also a substrate, albeit with a dramatically 
reduced initial rate that was only 8% that of the Abz-37mer peptide. The assay of the 
∆19 peptide fluorescence change over time was also only monophasic, suggesting that 
thioester formation has become rate limiting with this substrate. These results with 
truncated peptides demonstrate that the soluble heterotrimer recognizes at least part of 
the synthetic peptide substrate’s C-terminal signal sequence and is sensitive to 
substrate length much like the wild-type GPI-T is in vivo.81, 82, 87 
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Figure 2.8. The soluble GPI-T heterotrimer recognizes the propeptide’s C-terminal 
signal sequence. Traces of assays using truncated Abz-37mer peptide variants (Table 
2.2). The assays were performed with 10 mM NH2OH and 1 µM purified soluble 
heterotrimer. 
 
2.2.6 The soluble GPI-T heterotrimer exhibits specificity at the ω-site 
Experiments using an in vitro translation system with miniPLAP defined the 
requirements for a suitable ω-site for GPI-T cleavage.75, 76 Only mutation of miniPLAP’s 
ω-site (Asp484) to Gly, Ala, Asn, Ser, or Cys resulted in anchor attachment; other 
substitutions were not tolerated.77 To investigate whether our soluble GPI-T heterotrimer 
exhibits similar amino acid specificity at the ω-site, Abz-37mer peptide analogs were 
synthesized with Asp or Arg substituted for Ser12 (Table 2.2, S12D and S12R). 
Incubation of the S12D peptide with purified soluble heterotrimer and hydroxylamine 
resulted in an increase in fluorescence over time, as anticipated, with a rate that was 
62% of that of the parent Abz-37mer peptide (Figure 2.9, Table 2.3). In contrast, only a 
nominal fluorescence response was observed for the S12R peptide (a rate of 11% 
relative to the Abz-37mer peptide). These results demonstrate that the soluble GPI-T 
heterotrimer exhibits similar amino acid specificity at the ω-site as GPI-T in vivo.75 
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Figure 2.9. The soluble GPI-T heterotrimer exhibits specificity at the ω-site. Traces 
of assays conducted using peptides containing ω-site mutations (Table 2). The assays 
were performed with 10 mM NH2OH and 1 µM purified soluble heterotrimer. 
 
2.3 Discussion 
GPI anchoring of proteins is an essential post-translational modification.4 Efforts to 
understand the assembly and functions of subunits of GPI-T has been hindered by 
difficulties with protein expression and purification to any appreciable yield, as well as 
the absence of a reliable kinetic assay to measure GPI-T activity. In fact, it has remained 
unclear which subunits were essential for activity as Gpi8, Gaa1, and Gpi16 can be 
isolated with93 or without Gpi17 and Gab1,11, 96 suggesting that Gpi17 and Gab1 may 
play more peripheral roles. The results herein have addressed each of these challenges. 
Co-purification of the soluble domains of Gpi823-306, Gaa150-343, and Gpi1620-551 has 
enabled a simplified method to investigate the organization of this complex enzyme. 
Previous in vitro work characterizing different S. cerevisiae GPI-T soluble domains has 
demonstrated that: 1) Gpi823-306 assembles into a catalytically inactive homodimer;97 2) 
Gpi823-306 and Gaa150-343 assemble into an apparent dimer of dimers;100 and, 3) the 
luminal domain of Gpi1620-550 and Gpi823-306 do not stably interact when purified from 
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insect cells.93 Here we examined these three subunits when co-expressed in S. 
cerevisiae. Under the conditions used herein, co-immunoprecipitation and co-purification 
experiments conclusively demonstrated that Gpi1620-551 specifically interacts with Gpi823-
306 and Gaa150-343 independently of the third subunit. Furthermore, Gpi823-306-V5-His6, 
Gaa150-343-TAP, and Gpi1620-551-HA were successfully co-purified together for the first 
time. Given that Gpi823-306-V5-His6 and His6-Gaa150-343 assemble into an α2β2 dimer of 
dimers, we expect this complex to be symmetrical, with two copies of each subunit. 
Remarkably, this minimalistic GPI-T complex retained GPI-T-like catalytic activity, with 
respect to nucleophile dependence, C-terminal signal sequence length, and the identity 
of the ω-site residue.4 These results suggest that Gpi8, Gaa1, and Gpi16 comprise the 
catalytic core of full-length GPI-T.  
Activity of the truncated, soluble GPI-T complex was quantitatively measured herein 
using the in vitro peptide cleavage assay and a synthetic peptide substrate for GPI-T 
previously used to demonstrate that the purified, full-length GPI-T retained activity in 
vitro. The lack of a robust assay for GPI-T has previously hindered characterization of 
this enzyme in vitro. We anticipate that this assay will prove useful for future efforts to 
further characterize this enzyme. In particular, this assay will enable measurements to 
determine if and how the differential overexpression of individual GPI-T subunits impact 
GPI-T activity and substrate specificity, as a model system for the roles of GPI-T in 
cancer. 
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2.4 Methods 
2.4.1 Buffers and media 
Sc medium (1 L of 4X concentrated medium): 26.8 g yeast nitrogen base with 
ammonium sulfate and without amino acids and carbohydrates, 6.4 g drop-out mix 
without adenine, histidine, leucine, tryptophan, uracil, and yeast nitrogen base, and 0.4 g 
adenine and the appropriate amino acid(s) to select for desired plasmids. Calmodulin 
binding buffer: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM CaCl2, 1 mM DTT. 
Calmodulin elution buffer: 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM ethylene glycol-
bis(2-aminoethylether)-N,N,N’,N’--tetraacetic acid (EGTA), 1 mM DTT. Sodium 
phosphate lysis buffer: 50 mM NaH2PO4 pH 7.4, 300 mM NaCl, 10 mM imidazole, 5% 
glycerol. Sodium phosphate elution buffer: 50 mM NaH2PO4 pH 7.4, 300 mM NaCl, 300 
mM imidazole, 5% glycerol. TAP lysis buffer: 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 
10% glycerol, 0.1% Triton X-100. SDS gel loading dye (5X): 250 mM Tris-HCl, pH 6.8, 
10% SDS, 50% glycerol, 500 mM DTT, 0.25% bromophenol blue. Western blot transfer 
buffer (10X): 400 mM glycine, 500 mM Tris-HCl, pH 8.3, 13 mM SDS. Western blot 
transfer buffer (1X): Ten-fold dilution of 10X Western blot transfer buffer in 20% 
methanol and water. Tris buffered saline (TBS): 10 mM Tris-HCl, pH 7.5, 150 mM NaCl. 
TBS-T: TBS with 0.05% Tween 20. Assay buffer: 50 mM Tris-HCl, pH 7.0, 100 mM 
NaCl, 200 mM mannitol, 1 mM Tris(2-carboxyethyl)phosphine (TCEP), and 1 mM 
phenylmethylsulfonyl fluoride (PMSF). 
2.4.2 Cloning 
Cloning of pMNE023 has been described.100 Gateway cloning technology (Invitrogen, 
Carlsbad, CA, USA) was used to prepare pDGG107, pDDG115, pMND035, and 
pTJN056. For pDGG107, the open reading frame (ORF) of CPY-Gaa150-343 was 
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transferred from the pDONR221 donor vector to the pAG305GAL-ccdB destination 
vector (pAG305GAL-ccdB was a gift from Susan Lindquist; Addgene plasmid # 14137, 
Cambridge, MA, USA). This vector (pDGG107) contains a LEU2 marker and appends a 
C-terminal TAP tag onto CPY-Gaa150-343 to produce Gaa150-343-TAP after cleavage of the 
N-terminal CPY signal sequence. The ORF of Gpi161-551 was cloned into pDONR221 
and then transferred to three separate destination vectors. These plasmids were 
pMNE035: pYES-DEST52 (Invitrogen), which contains a GAL1 promoter, URA3 marker, 
and appends C-terminal V5 and His6 affinity purification tags to Gpi161-551 to produce 
Gpi1620-551-V5-His6. pTJN056: pAG305GAL-ccdB, (pAG305GAL-ccdB was a gift from 
Susan Lindquist; Addgene plasmid # 14137), which contains a GAL1 promoter, LEU2 
marker, and appends a C-terminal TAP tag to Gpi161-551 to produce Gpi1620-551-TAP. 
pDGG115: pAG414GAL-ccdB, (pAG414GAL-ccdB was a gift from Susan Lindquist; 
Addgene plasmid # 14143), which contains a GAL1 promoter, TRP1 marker, and 
appends a C-terminal HA tag to Gpi161-551 to produce Gpi1620-551-HA after N-terminal 
cleavage of the ER signal sequence. 
2.4.3 Western blot analyses 
For all Western blots, samples were separated by SDS-PAGE and then transferred 
to 0.45 µm immobilon-FL polyvinylidene fluoride (PVDF) membranes (Millipore Sigma, 
St. Louis, MO, USA) that had been pre-activated by soaking in methanol for 5 min, 
followed by a 10 min incubation in 1X Western blot transfer buffer with the gels. The 
transfers were performed at 200 mA for 30 min per gel. The membranes were blocked in 
5% non-fat dried milk in TBS-T for 2 h or overnight at room temperature. Each 
membrane was washed with TBS-T 3X for 5 min each time before and after incubation 
with the primary and secondary antibodies, followed by a wash with TBS immediately 
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before imaging. The primary antibody solutions were prepared at the following 
concentrations in 1% BSA: anti-HA (1 µg/mL, Sigma-Aldrich #H3663, St. Louis, MO, 
USA), anti-Protein A (1:1,000, Sigma-Aldrich #P3775), and anti-V5 (1 µg/mL, 
ThermoFisher #MA5-15253). The membranes were incubated for 2 h at room 
temperature. Goat anti-mouse (Anaspec #AS-61057-05-H647, Fremont, CA, USA) or 
goat anti-rabbit HiLyte Fluor647-conjugated IgG (Anaspec #AS-61056-05-H647) were 
used at 1 µg/mL in 1% BSA as secondary antibodies. Each Western blot was visualized 
using a Typhoon FLA 9500 scanner (GE Healthcare Life Sciences, Marlborough, MA, 
USA). 
2.4.4 Gpi1620-551-V5-His6 overexpression and purification by Ni2+-NTA 
pMNE035 was transformed into InvSc1 competent yeast cells by lithium acetate 
transformation after DTT pre-treatment.42 Overnight cultures were grown in 1X Sc-ura 
selection medium with 2% glucose at 30 °C. This culture was used to inoculate a 100 mL 
culture with the same medium and 1% glucose. Each culture was grown to an OD600 = 
0.4 followed by the addition of 2% galactose to induce protein overexpression. The cells 
were grown for 12 h at 30 °C prior to harvesting for purification. 
All purification steps were performed at 4 °C. The cell pellet was resuspended in 1 
mL sodium phosphate lysis buffer with PMSF and an ethylenediaminetetraacetic acid 
(EDTA)-free cOmplete protease inhibitor cocktail tablet (Millipore Sigma). The lysate was 
clarified by centrifugation at 14,000 RPM for 30 min. The resulting supernatant was 
passed through a 1 mL Ni2+-NTA HiTrap column. After elution of the supernatant, the 
resin was washed with 5 mL lysis buffer. Gpi1620-551-V5-His6 was eluted from the resin by 
the addition of 5 column volumes of sodium phosphate lysis buffer with 300 mM 
imidazole. This eluant was concentrated to 200 µL with a 30 kDa molecular weight cutoff 
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centrifugal filter and glycerol was added to 50%. A 100 µL sample of this eluant was 
incubated with or without 1 kU endoglycosidase Hf for 1 h at 37 oC. Samples were 
loaded onto an SDS-PAGE gel and transferred to a PVDF membrane for Western 
blotting. 
2.4.5 Gpi823-306-V5-His6:Gpi1620-551-HA and Gaa150-343-TAP:Gpi1620-551-V5-His6 
overexpression and co-immunoprecipitation 
pDGG107 and pMNE035 or pMNE023 and pDGG115 were transformed in 
competent InvSc1 cells by lithium acetate transformation after DTT pre-treatment.139 
Cultures were grown overnight in the appropriate medium (1X Sc-ura-leu for 
Gaa1:Gpi16 and 1X Sc-ura-trp for Gpi8:Gpi16) with 2% glucose at 30 °C. These starter 
cultures were used to inoculate 100 mL cultures with the same selective medium and 
1% glucose at 30 °C. Each culture was grown to an OD600 = 0.4 followed by the addition 
of 2% galactose to induce protein overexpression. The cells were grown for 12 h at 30 
°C prior to harvesting for purification. 
All co-immunoprecipitation steps for each heterodimer were performed at 4 °C 
unless noted otherwise. The cell pellet overexpressing the Gaa150-343-TAP:Gpi1620-551-
V5-His6 heterodimer was resuspended in 1 mL TAP purification lysis buffer and 1X 
EDTA-free cOmplete protease inhibitors (Millipore Sigma). The cells were lysed by 
vortexing with 1 mL of 0.5 mm glass beads for 8 x 30 s pulses with a 30 s incubation on 
ice between each pulse. The lysate was clarified by centrifugation at 14,000 RPM for 30 
min. An aliquot of the supernatant was added to SDS-PAGE loading dye and the 
remaining supernatant was incubated with 500 µL IgG sepharose pre-washed with the 
lysis buffer for 2 h. The resin was centrifuged at 2,000 RPM for 5 min and an aliquot of 
the decanted unbound fraction was collected for SDS-PAGE analyses. The resin was 
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washed five times with 1 mL TAP purification lysis buffer with a 1 min incubation 
between each wash. The immunoprecipitated heterodimer was eluted from the IgG resin 
with 500 µL 500 mM acetic acid for 10 min at room temperature. The IP samples were 
loaded onto two 10% SDS-PAGE gels and transferred to PVDF membranes for Western 
blotting. The volume of each sample was adjusted such that a total OD280 of 100 was 
loaded into each lane. 
The cell pellet overexpressing Gpi823-306-V5-His6:Gpi1620-551-HA was resuspended 
and lysed, and the lysate was clarified using the same protocol mentioned above for the 
Gaa150-343-TAP:Gpi1620-551-V5-His6 heterodimer. An aliquot of the supernatant was 
added to SDS-PAGE loading dye and the remaining supernatant was incubated with 20 
µg anti-HA primary antibody overnight. Protein A/G PLUS-Agarose resin (Santa Cruz 
Biotechnology #sc-2003, Dallas, TX, USA), pre-washed with lysis buffer, was added to 
the lysate-antibody mixture and incubated for 4 h. This resin was centrifuged at 2,000 
RPM for 5 min and an aliquot of the supernatant was collected to analyze the unbound 
fraction. The resin was washed three times with 1 mL TAP purification lysis buffer with a 
1 min spin between each wash. The beads were boiled in 100 µL 1X SDS gel loading 
dye to elute the immunoprecipitated heterodimer. The beads were centrifuged and the 
resulting supernatant was collected. The IP samples were loaded onto two SDS-PAGE 
gels and transferred to PVDF membranes for Western blotting. The volume of each 
sample was adjusted such that a total OD280 of 100 was loaded into each lane. 
2.4.6 Soluble heterotrimer overexpression and purification from S. cerevisiae 
Each of the plasmids (pDGG107, pMNE023, and pDGG115) were transformed into 
InvSc1 competent yeast cells as described above.139 Overnight cultures were grown in 
1X Sc-ura-trp-leu selection medium with 2% glucose at 30 °C. This culture was used to 
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inoculate a 1 L culture with the same medium and 1% glucose. Each culture was grown 
to an OD600 = 0.4 followed by the addition of 2% galactose to induce protein 
overexpression. The cells were grown for 12 h at 30 °C prior to harvesting for 
purification. 
All purification steps were performed at 4 °C. The cell pellet was resuspended in 8 
mL calmodulin binding buffer with PMSF and an EDTA-free cOmplete protease inhibitor 
cocktail tablet. (The protease inhibitor cocktail tablet was not added when purifying the 
soluble heterotrimer for kinetic assays to avoid disruption of activity by modification of 
the active site cysteine in Gpi8.) The lysate was clarified by centrifugation at 14,000 
RPM for 30 min. The resulting supernatant was incubated with calmodulin-sepharose 
resin (1 mL of resin for 8 mL of supernatant) for 2 h. After flow-through of the 
supernatant, the resin was washed with 5 column volumes of calmodulin binding buffer. 
The soluble heterotrimer was eluted from the resin by the addition of 5 column volumes 
of calmodulin elution buffer. This eluent was concentrated to 500 µL with a 30 kDa 
molecular weight cutoff centrifugal filter. Aliquots from this purification were loaded onto 
three SDS-PAGE gels and protein bands were visualized by Western blot analyses. 
(10% gels were used to visualize Gaa1 and Gpi16 and a 12% gel for Gpi8). The volume 
of each sample was adjusted such that a total OD280 of 100 was loaded into each lane. 
2.4.7 Peptide synthesis and purification 
Peptide synthesis reagents were purchased from Advanced ChemTech unless noted 
otherwise. The Abz-37mer peptide was synthesized on a Prelude peptide synthesizer 
(Protein Technologies) using standard 9-fluorenylmethoxycarbonyl (Fmoc) and O-
(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU) methods 
with pre-substituted Fmoc-Ser(tBu)-Wang resin (1.1 g, 100-200 mesh, 0.84 mmol/g).140 
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The Fmoc protecting group was removed by treating the resin with 5 mL of 20% 
piperidine (Sigma) in N-methyl-2-pyrrolidinone (NMP) for 10 min at room temperature. 
Each amino acid was double- or triple-coupled with a solution of Fmoc-AA (2.5 equiv), 
HBTU (2.5 equiv), and N,N’-diisopropylethylamine (DIPEA, 10 equiv) in 5 mL of NMP for 
1 h at room temperature. A Kaiser test was performed to monitor each Fmoc 
deprotection and amino acid coupling.140 The resin was capped with 1:1:3 mL acetic 
anhydride:DIPEA:NMP for 15 min after the last coupling of each amino acid.  
The Abz-37mer peptide was cleaved from the Wang resin with 1 mL 95:2.5:2.5 
trifluoroacetic acid (TFA):anisole:triisopropylsilane for every 100 mg of resin for 1 h at 
room temperature. The peptide was precipitated and washed with cold diethyl ether and 
lyophilized. The dry, crude precipitate was resuspended in 0.1% TFA in 1:1 acetonitrile 
(ACN):water and purified by RP-HPLC (C18 Atlantis Prep T3 5.0 µm 10 mm x 250 mm 
column, Waters Corporation, Milford, MA, USA) with a gradient of 58-60% ACN over 20 
min at 2 mL/min with 0.1% TFA in all solvents. The peptide was confirmed by ESI-MS: 
Calculated (m+3H)3+ = 1400 m/z, observed 1400 m/z; calculated (m+4H)4+ = 1050 m/z, 
observed 1050 m/z; calculated (m+5H)5+ = 840 m/z, observed 840 m/z; calculated 
(m+6H)6+ 700 m/z, observed 700 m/z. A stock solution of the Abz-37mer peptide (1 mM) 
was prepared in dimethylsulfoxide (DMSO) and was stored at -20 °C. 
2.4.8 Synthesis and purification of the Abz-12mer hydroxamic acid peptide 
standard 
The parent Abz-12mer peptide was synthesized as described above but on 2-
chlorotrityl chloride resin (2-CTC resin, 250 mg, 1.0 – 1.2 mequiv/g, 200 – 400 mesh) to 
enable downstream modification of the peptide C-terminus.140 The resin was swelled 
with 2.5 mL of dichloromethane (DCM) for 15 min at room temperature. Fmoc-Ser(tBu)-
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OH (5 equiv) was substituted onto the 2-CTC resin with a solution of DIPEA (5 equiv) in 
5 mL of DCM for 2 h to a final loading of 0.6 mmol/g. The peptide was not capped after 
each coupling to prevent cleavage of the peptide from the 2-CTC resin. 
The side chain-protected Abz-12mer carboxylic acid was cleaved from the 2-CTC 
resin with 2.5 mL 1:1:8 glacial acetic acid:trifluoroethanol:DCM for 30 min at room 
temperature.141 The peptide was precipitated and washed with 25 mL hexanes. 
Hydroxylamine (10 equiv) was coupled to the C-terminus of the Abz-12mer carboxylic 
acid peptide with a solution of HBTU (10 equiv) and DIPEA (20 equiv) in 3 mL NMP for 3 
h at room temperature. The crude Abz-12mer hydroxamic acid peptide and unreacted 
starting material were precipitated and washed with diethyl ether. The protecting groups 
were cleaved from the peptides with 1 mL 95:2.5:2.5 TFA:anisole:triisopropylsilane for 1 
h at room temperature. The resulting dry, crude precipitated peptide was resuspended in 
1 mL 10% ACN in water with 0.1% TFA and purified by RP-HPLC (C18 Atlantis Prep T3 
5.0 µm 10 mm x 250 mm column, Waters Corporation) with a gradient of 15 – 20% 
solvent B (70% ACN) over 20 min, followed by a gradient of 20 – 95% solvent B gradient 
over 15 min at 2 mL/min with 0.1% TFA in all solvents. The peptide was confirmed by 
ESI-MS. Abz-12mer hydroxamic acid: Calculated (m+2H)2+ = 693 m/z, observed 693 
m/z. 
A stock solutions of the Abz-12mer hydroxamic acid peptide (1 mM) was prepared in 
dimethylsulfoxide (DMSO) and was stored at -20 °C. 
2.4.9 In vitro peptide cleavage assays 
The Abz-37mer peptide (10 µM from a 1 mM stock solution in DMSO) was incubated 
in assay buffer (freshly prepared before assays) for two min at room temperature prior to 
reaction initiation. Fluorescence intensity was measured using a Cary Eclipse 
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fluorescence spectrophotometer (Varian, Santa Clara, CA, USA) after the addition of 
purified soluble heterotrimer (1 µM final concentration) at room temperature for 10 min 
every 1 s with an excitation wavelength of 321 nm and an emission wavelength of 417 
nm with slit widths of 10 nm. Each assay was performed in triplicate. Initial rates are 
reported as averages with standard deviations in Table 2.3. 
2.4.10 Product analyses by LC-MS 
Assays performed for 1 h at room temperature were quenched with TFA and 
acetonitrile to final concentrations of 0.25% and 10%, respectively. Reaction mixtures 
were injected onto a C18 Atlantis Prep HPLC column (T3 5.0 µm 10 mm x 250 mm 
column; Waters Corporation) and eluted with a 15-20% solvent B gradient over 20 min 
followed by a 20-95% solvent B gradient over 15 min, both at a 2 mL/min flow rate. 
Peaks were collected manually, lyophilized overnight, resuspended in 0.1% formic acid 
and 5% DMSO in 10% acetonitrile, and analyzed by ESI-MS (direct injection onto an 
LCMS-2020, Shimadzu Corporation, Kyoto, Japan). Solvent A: 0.1% TFA in water. 
Solvent B: 0.1% TFA in 70% acetonitrile/water. 
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CHAPTER 3 CONCLUSIONS AND FUTURE DIRECTIONS 
3.1 Dissertation research conclusions 
GPI membrane anchoring of proteins is an essential post-translational modification.4 
The enzyme complex that catalyzes this process, GPI-T, remains poorly understood, 
despite the discovery of its first subunit more than two decades ago.8 The S. cerevisiae 
GPI-T is composed of five membrane-bound subunits: Gpi8, Gaa1, Gpi16, Gpi17, and 
Gab1.13 Gpi8, Gaa1, and Gpi16 form an isolatable complex with93 and without Gpi17 and 
Gab1.11, 96 Our understanding of GPI-T assembly, subunit stoichiometry and function, 
and other fundamental biochemical characteristics of this enzyme have been greatly 
hindered by its poor expression, difficult purification, and the lack of a reliable, 
quantitative assay that measures the activity of purified GPI-T. In this dissertation, 
solutions to each of these problems are presented. 
Prior to this work, computational programs had been used to predict soluble domains 
to simplify expression and purification of each core subunit, and the biochemical 
characterization of Gpi823-30697 and the Gpi823-306:Gaa150-343 heterodimer100 had been 
reported. Gpi8, the catalytic subunit,15 is predicted to contain two soluble domains; the 
structural model of the larger of the two domains (Gpi823-306) possesses sequence and 
structural similarity to caspases; the smaller domain is not homologous to any known 
protein (Figure 1.7).97 GST-Gpi823-306 was stably overexpressed and purified from E. coli. 
Native PAGE and MALDI-TOF MS analyses after purification revealed that Gpi823-306 
assembles and purifies as a homodimer.97 These results are consistent with caspases, 
which are active upon homodimerization.142 Gpi823-306 can bind peptide substrates in 
vitro, but it is catalytically inactive, suggesting that one or more of the other GPI-T 
subunits is necessary for activity.97 
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Co-overexpression, co-purification, and characterization of GST-Gpi823-306 and His6-
Gaa150-343 from E. coli demonstrated that these two subunits assemble into a complex, 
consistent with a dimer of dimers (an α2β2 stoichiometry).100 Using similar design and 
expression approaches, Gpi823-306-V5-His6 and Gaa150-343-HA were overexpressed in S. 
cerevisiae. Immunoprecipitation of Gaa150-343-HA resulted in co-immunoprecipitation of 
Gpi823-306-V5-His6.100 These data together demonstrate that the soluble domains of Gpi8 
and Gaa1 assemble into a stable heterodimeric complex without a requirement for Gpi16 
(Figure 3.1a). 
Chapter 2 detailed efforts to further understand how the S. cerevisiae core GPI-T 
heterotrimer (Gpi8:Gaa1:Gpi16)11 assembles and functions. Similar expression and 
protein-protein interaction experiments were performed to determine whether Gpi1620-551 
assembles into separate heterodimeric complexes with Gpi823-306 and Gaa150-343 without 
a requirement for the third subunit. Co-immunoprecipitations and co-purification 
experiments demonstrate that Gpi1620-551 forms specific, noncovalent interactions with 
Gpi823-306 and Gaa150-343 without a need for the soluble domain of the remaining subunit 
(Figures 2.3, 2.4, and 3.1a). The structural prediction and subunit overexpression 
methods presented in this chapter have not only been instrumental to understand how 
the core GPI-T heterotrimer assembles in S. cerevisiae, but may also be useful to 
express, purify, and characterize other membrane-bound proteins. 
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Figure 3.1. Cartoon representations of the GPI-T heterodimeric and heterotrimeric 
complexes investigated in Chapter 2. Each soluble domain stably interacts with every 
other subunit (panel a) and Gpi823-306, Gaa150-343, and Gpi1620-551 assemble and co-purify 
as a heterotrimeric complex without their TM domains (panel b). 
 
Purification of Gaa150-343-TAP resulted in the co-purification of Gpi823-306-V5-His6 and 
Gpi1620-551-HA to demonstrate that the TM domains of each subunit are not necessary 
for assembly and purification of the S. cerevisiae soluble GPI-T heterotrimer (Figure 2.5 
and 3.1b). Importantly, the data in Chapter 2 also reveal that this minimalistic GPI-T 
heterotrimer remains catalytically active (Figure 2.7). Activity was demonstrated using an 
internally-quenched synthetic peptide substrate based on CD52, the smallest known 
GPI-AP, in nucleophile- and time-dependent manners.83 Using this fluorescence assay, 
results in Chapter 2 further demonstrate that this soluble core GPI-T heterotrimer 
recognizes its substrates and exhibits specificity at the ω-site similar to the full-length, 
membrane-bound enzyme in vivo (Figures 2.8-2.9).75, 81, 82, 87 
The assay presented here using the soluble GPI-T heterotrimer, and the system 
developed and optimized by Dr. Ekanayaka using the full-length GPI-T, are the first in 
vitro methods to quantitatively measure the activity of purified GPI-T in a time-dependent 
manner. These results come nearly three decades after the development of the first in 
vivo method to measure GPI-T activity76 and more than 10 years after the discovery of 
the fifth, and presumably final, subunit.13 The development of this assay will allow for 
unprecedented investigations into how subunit expression affects GPI-T activity. Varying 
the concentrations of individual GPI-T subunits to mimic different cancer types may help 
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us understand how this enzyme is involved in cancer initiation, progression, and 
metastasis. For the first time, potential GPI-T inhibitors may also be screened in a high-
throughput manner using this in vitro assay. Altogether, these data open new directions 
for further research on this complicated enzyme. 
3.2 Future directions for GPI-T research 
While great strides in our knowledge of GPI-T have been made by characterizing the 
assembly of the S. cerevisiae soluble GPI-T heterotrimer and the development of an 
assay to measure purified GPI-T activity, there are many aspects of this complex 
enzyme that remain unclear, including the roles of Gpi17 and Gab1 and how GPI-T 
activity changes in cancer initiation and progression. The in vitro assay developed by our 
laboratory may be useful to study how changes in subunit expression levels affect 
overall GPI-T activity. The assays may be performed with purified full-length or truncated 
GPI-T subunits to mimic their expression in different cancers.16 
The methods reported by our laboratory to characterize Gpi823-30697 and the Gpi823-
306:Gaa150-343 complex100 may be useful to investigate other aspects of GPI-T assembly; 
i.e. Does the heterotrimer assemble into a heterohexamer? Native PAGE analysis of the 
membrane-solubilized Gpi8:Gaa1:Gpi16 heterotrimeric complex from S. cerevisiae 
revealed two bands from 440 to 660 kDa, suggesting that more than one copy of each 
subunit was purified.11 Our laboratory has reported that Gpi823-306 assembles into a 
homodimer97 and Gpi823-306:Gaa150-343 forms a complex with an apparent α2β2 
stoichiometry.100 Human PIG-K and PIG-T are covalently linked via a disulfide bond, but 
the S. cerevisiae orthologs are not.93, 106 Altogether, the reported GPI-T subunit 
stoichiometry data with the heterodimer assembly data in Chapter 2 (Figures 2.3-2.4) 
suggests that the GPI-T heterotrimer assembles into a heterohexameric complex. 
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Co-immunoprecipitation or co-purification experiments, as well as quantitative 
methods (e.g. surface plasmon resonance) may be performed with the soluble domain of 
Gpi17 to understand whether this subunit interacts with individual or any combination of 
GPI-T subunits. While Gpi17 and Gab1 can purify with93 and without11, 96 the S. 
cerevisiae core GPI-T heterotrimer, and the minimalistic, soluble GPI-T is catalytically 
active in vitro, human Gpi17 and Gab1 (PIG-S and PIG-U, respectively) are both 
necessary for GPI anchoring of proteins in vivo.12, 13 Co-immunoprecipitation and co-
purification techniques may fail to capture weak binding partners. Covalent cross-linking 
techniques143 and proximity ligation assays144 are powerful techniques that could be 
used to further study GPI-T assembly and stoichiometry, as well as the roles of each 
individual subunit. 
Gpi8 likely contains most of GPI-T’s active site with its Cys-His dyad (Cys199 and 
His157 in S. cerevisiae).15 Gaa1 is similar to zinc-dependent aminopeptidases and may 
contain the rest of the active site.100, 101 Although the soluble, core GPI-T heterotrimer 
retains transamidase activity in vitro, it is unclear how GPI-T recognizes its substrates. 
Several methods, discussed in the following sections, may be useful to understand how 
GPI-T recognizes its proprotein and GPI anchor substrates. Gpi17 is not homologous to 
any known protein and its function remains unclear.4 Gaa1 and Gab1 are proposed to 
recognize the GPI anchor. 13, 103 
3.2.1 Proprotein recognition by GPI-T 
GPI-T recognizes the C-terminal signal sequence of the proprotein substrate.4 It is 
hypothesized that, since the hydrophobic region of C-terminal signal sequences do not 
possess a consensus sequence, a large, hydrophobic pocket may exist that can 
accommodate a wide range of amino acids. Gpi8 and Gaa1 cross-linked to a 
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photoreactive miniPLAP substrate, but it is unclear how these subunits or if other 
subunits are involved in proprotein recognition.98 Synthesis of peptide substrates based 
on the proproteins of S. cerevisiae GPI-APs with photoreactive amino acids (e.g. p-
benzoyl-L-phenylalanine145) can be used to cross-link with yeast GPI-T; the soluble 
heterotrimer and/or the full-length enzyme. The substitution with or addition of 
propargylGly in the peptide substrate’s C-terminus offers another possible scenario to 
identify GPI-T subunits involved in proprotein recognition. This propargylGly modification 
will allow visualization of cross-linked species via Click reaction with an azide-conjugated 
fluorophore.146 Reaction of the propargyl functional group with biotin-azide will assist with 
the identification of cross-linked adducts after streptavidin pull-down and LC-MS/MS 
analyses (Figure 3.2). 
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Figure 3.2. A general photocross-linking strategy to capture GPI-T subunit(s) 
involved in proprotein substrate recognition.145 UV irradiation of a photoreactive 
propeptide substrate in the vicinity of GPI-T would induce cross-linking between the 
photoreactive amino acid (orange circle) and subunit(s). A Click reaction between the 
cross-linked adduct and biotin-N3, followed by streptavidin pull-down would enrich this 
complex. Trypsin digestion, followed by LC-MS/MS analyses would reveal the GPI-T 
subunit(s) involved in propeptide recognition. 
 
3.2.2 GPI anchor recognition by GPI-T 
Gaa1 and Gab1 are proposed to have roles in GPI anchor recognition.13, 103 Gaa1 is 
a large subunit with six TM domains and one lumenal domain.8 Various truncation and 
site-directed mutagenesis experiments revealed a conserved residue in the last TM 
domain, Pro609, and the Pro609Leu mutation abolished Gaa1’s ability to 
immunoprecipitate with the GPI anchor substrate.103 This proline residue may act as a 
hinge to orient the GPI anchor towards GPI-T’s active site.103 Gab1 contains sequence 
similarity to fatty acid elongases and may also recognize the GPI anchor.13 
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Full-length or truncated GPI anchor analogs69 that contain benzophenone may be 
used to study how GPI-T binds the glycan moiety of its GPI anchor substrate. A similar 
approach described above to identify GPI-T subunit(s) involved in proprotein substrate 
recognition would be applicable for GPI anchor substrates. 
3.3 Conclusions 
The data in this dissertation presents answers to fundamental GPI-T questions that 
had been elusive. An assay has been developed to measure the activity of both the 
purified full-length and truncated, soluble core GPI-T heterotrimers.108 These systems 
allow for a wide array of experiments to study the impact each subunit has on overall 
GPI-T activity. Optimized overexpression and purification of Gpi823-306, Gaa150-343, 
Gpi1620-551 will allow for structural experiments. Small-angle x-ray scattering or x-ray 
crystal structures of each individual subunit, the heterodimeric complexes, and the core 
GPI-T heterotrimer would allow us to better understand how the subunits interact with 
one another or how GPI-T recognizes its substrates. Future research on GPI-T will 
clarify how this complicated enzyme and post-translational modification are involved in 
normal cellular function and cancer. 
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APPENDIX A FULL-LENGTH WESTERN BLOT IMAGES 
The full-length Western blots for Figures 2.3-2.5 and the control immunoprecipitation 
experiments discussed in section 2.2.2 are listed in this appendix. 
 
 
Figure A.1. Gpi823-306-V5-His6 alone does not immunoprecipitate with anti-HA 
antibodies. Gpi823-306-V5-His6 was overexpressed in S. cerevisiae and lysates were 
incubated with anti-HA antibodies following the protocols used for the Gpi823-306-V5-
His6:Gpi1620-551-HA soluble heterodimer co-immunoprecipitation. Input: Clarified 
supernatant after lysis. U: Unbound fraction after IP. E: Elution fraction. These fractions 
were separated on a 12% SDS-PAGE gel and visualized by an anti-V5 Western blot. 
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Figure A.2. Gpi823-306-V5-His6 co-purifies with Gpi1620-551-TAP in the presence of 1 
mM DTT. Purification of Gpi1620-551-TAP from S. cerevisiae lysate, following the 
calmodulin-sepharose purification protocol, results in the co-purification of Gpi823-306-V5-
His6, even in the presence of 1 mM DTT. Western blots were transferred from SDS-
PAGE gels run in parallel using the same samples. Input: Clarified supernatant after 
lysis. U: Unbound fraction. E: Elution fraction. Top panel: Anti-Protein A Western blot 
confirmation of Gpi1620-551-TAP. Bottom panel: Anti-V5 Western blot confirmation of 
Gpi823-306-V5-His6. 
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Figure A.3. Gpi1620-551-V5-His6 alone does not immunoprecipitate with IgG. Gpi1620-
551-V5-His6 was overexpressed in S. cerevisiae and lysates were incubated with IgG 
sepharose following the protocols used for the Gaa150-343-TAP:Gpi1620-551-V5-His6 
soluble heterodimer co-immunoprecipitation. Input: Clarified supernatant after lysis. U: 
Unbound fraction after IP. E: Elution fraction. These fractions were separated on a 10% 
SDS-PAGE gel and visualized by an anti-V5 Western blot. 
  
74 
 
 
 
Figure A.4. Gpi823-306-V5-His6 and Gpi1620-551-HA assemble into and 
immunoprecipitate as one complex. Full-length images of Figure 2.3 are shown 
above. Input: Clarified supernatant after lysis and prior to IP. U: Unbound fraction after 
IP. E: Elution fraction. Top panel: Anti-HA Western blot confirmation of Gpi1620-551-HA. 
Bottom panel: Anti-V5 Western blot confirmation of Gpi823-306-V5-His6.  
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Figure A.5. Gaa150-343-TAP and Gpi1620-551-V5-His6 assemble into and 
immunoprecipitate as one complex. Full-length images of the blots from Figure 2.4 
are shown here. Input: Clarified supernatant after lysis and prior to IP. U: Unbound 
fraction after IP. E: Elution fraction. Top panel: Anti-Protein A Western blot confirmation 
of Gaa150-343-TAP. Bottom panel: Anti-V5 Western blot confirmation of Gpi1620-551-V5-
His6. 
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Figure A.6. Gpi823-306-V5-His6, Gaa150-343-TAP, and Gpi1620-551-HA assemble into and 
purify as a single, heterotrimeric complex. Full-length images of the Western blots in 
Figure 2.5b are shown here. Purification of Gaa150-343-TAP from S. cerevisiae cell lysate 
results in the simultaneous co-purification of both Gpi823-306-V5-His6 and Gpi1620-551-HA. 
These subunits were visualized in the eluant by anti-Protein A (panel a), anti-V5 (panel 
b), and anti-HA (panel c) Western blots. Samples were also treated with Endo Hf to 
remove any glycosylation for comparison. Input: Clarified supernatant after lysis. U: 
Unbound fraction. E: Elution fraction. The Western blots shown in each of the panels 
were transferred from three SDS-PAGE gels performed in parallel with the same 
samples. 
  
77 
 
APPENDIX B HPLC AND ESI-MS ANALYSES FROM THE ABZ-37MER SYNTHESIS 
AND CHAPTER 2 
 
Table B.1. Number of coupling reactions performed for each amino acid residue 
during the CD52 Abz-37mer peptide synthesis. 
 
Residue Number of coupling reactions prior to capping 
HPLC and/or ESI-MS 
analyses in figure: 
F Double - 
H Double - 
F Double - 
L Double B.1 
H Double - 
I Double - 
I Double B.2 
A Triple - 
N Double B.3 
A Double - 
V Triple B.4 
F Double - 
F Double B.5 
L Triple - 
F Triple - 
I Double B.6 
G Triple - 
G Double - 
S Triple - 
Y* Quadruple B.7 – 8 
N Triple - 
K Double - 
S Double - 
A Double B.9 
S Double - 
P Double - 
S Double - 
S Double - 
K Double B.10 – 11  
E Triple B. 12 – 13  
S Triple B. 14 – 15  
T Double - 
D Triple B. 16 – 17  
K Triple - 
Q Triple - 
G Double - 
Abz Double B. 18 – 19  
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The Abz-37mer peptide was synthesized on pre-substituted Fmoc-Ser(tBu)-Wang 
resin (1.1 g, 100-200 mesh, 0.84 mmol/g). Refer to section 2.4.7 for the protocol. The 
synthesis was monitored at various stages by cleaving a small sample of peptide and 
evaluating it by HPLC and ESI-MS. This appendix lists the peptide analysis data. The 
crude CD52 5mer, Fmoc-8mer, Fmoc-10mer, Fmoc-12mer, Fmoc-14mer, and Fmoc-
17mer were analyzed by ESI-MS. The CD52 21mer, 30mer, 31mer, 32mer, and 34mer 
were purified by RP-HPLC (Zorbax SB-C3 4.6 mm x 250 mm column, Agilent 
Technologies) with a gradient of 40-80% ACN over 40 min at 1 mL/min with 0.1% TFA in 
all solvents. The mass spectra of these intermediates are shown in the following figures. 
 
Figure B.1. ESI mass spectrum of the crude CD52 5mer. Exact mass = 649 g/mol. 
Observed (m+H)+ = 650 m/z, (m+Na)+ = 672 m/z, (m+2H)2+ = 326 m/z. Calculated 
(m+H)+ = 650 m/z, (m+Na)+ = 672 m/z, (m+2H)2+ = 326 m/z. 
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Figure B.2. ESI mass spectrum of the crude CD52 Fmoc-8mer. Exact mass = 1235 
g/mol. Observed (m+H)+ = 1236 m/z, (m+2H)2+ = 618 m/z. Calculated (m+H)+ = 1236 
m/z, (m+2H)2+ = 618 m/z. 
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Figure B.3. ESI mass spectrum of the crude CD52 Fmoc-10mer. Exact mass = 1420 
g/mol. Observed (m+H)+ = 1421 m/z, (m+2H)2+ = 711 m/z, (m+3H)3+ = 475 m/z. 
Calculated (m+H)+ = 1421 m/z, (m+2H)2+ = 711 m/z, (m+3H)3+ = 474 m/z. 
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Figure B.4. ESI mass spectrum of the crude CD52 Fmoc-12mer. Exact mass = 1590 
g/mol. Observed (m+H)+ = 1591 m/z, (m+2H)2+ = 796 m/z. Calculated (m+H)+ = 1591 
m/z, (m+2H)2+ = 796 m/z. 
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Figure B.5. ESI mass spectrum of the crude CD52 Fmoc-14mer. Exact mass = 1884 
g/mol. Observed (m+H)+ = 1885 m/z, (m+2H)2+ = 943 m/z. Calculated (m+H)+ = 1885 
m/z, (m+2H)2+ = 943 m/z. 
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Figure B.6. ESI mass spectrum of the crude CD52 Fmoc-17mer. Exact mass = 2257 
g/mol. Observed (m+2H)2+ = 1130 m/z, (m+3H)3+ = 754 m/z. Calculated (m+2H)2+ = 
1130 m/z, (m+3H)3+ = 753 m/z. 
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Figure B.7. HPLC purification of the CD52 21mer. The CD52 21mer was purified by 
RP-HPLC (Zorbax SB-C3 4.6 mm x 250 mm column, Agilent Technologies) with a 
gradient of 40-80% ACN over 40 min at 1 mL/min with 0.1% TFA in all solvents and the 
UV-visible detector was set to 254 nm. 
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Figure B.8. ESI mass spectrum of the purified of CD52 21mer. Exact mass = 2444 
g/mol. Observed (m+2H)2+ = 1224 m/z, (m+3H)3+ = 816 m/z. Calculated (m+2H)2+ = 
1223 m/z, (m+3H)3+ = 816 m/z. 
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Figure B.9. ESI mass spectrum of the crude CD52 25mer. Exact mass = 2844 g/mol. 
Observed (m+2H)2+ = 1424 m/z, (m+3H)3+ = 950 m/z, (m+4H)4+ = 712 m/z. Calculated 
(m+2H)2+ = 1423 m/z, (m+3H)3+ = 949 m/z, (m+4H)4+ = 712 m/z. 
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Figure B.10. HPLC purification of the CD52 30mer. The CD52 30mer was purified by 
RP-HPLC (Zorbax SB-C3 4.6 mm x 250 mm column, Agilent Technologies) with a 
gradient of 40-80% ACN over 40 min at 1 mL/min with 0.1% TFA in all solvents and the 
UV-visible detector was set to 254 nm. 
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Figure B.11. ESI mass spectrum of the purified of CD52 30mer. Exact mass = 3331 
g/mol. Observed (m+2H)2+ = 1667 m/z, (m+3H)3+ = 1112 m/z, (m+4H)4+ = 834 m/z, 
(m+5H)5+ = 667 m/z. Calculated (m+2H)2+ = 1666 m/z, (m+3H)3+ = 1111 m/z, (m+4H)4+ = 
834 m/z, (m+5H)5+ = 667 m/z. 
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Figure B.12. HPLC purification of the CD52 31mer. The CD52 31mer was purified by 
RP-HPLC (Zorbax SB-C3 4.6 mm x 250 mm column, Agilent Technologies) with a 
gradient of 40-80% ACN over 40 min at 1 mL/min with 0.1% TFA in all solvents and the 
UV-visible detector was set to 254 nm. 
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Figure B.13. ESI mass spectrum of the purified of CD52 31mer. Exact mass = 3331 
g/mol. Observed (m+2H)2+ = 1731 m/z, (m+3H)3+ = 1155 m/z, (m+4H)4+ = 866 m/z. 
Calculated (m+2H)2+ = 1731 m/z, (m+3H)3+ = 1154 m/z, (m+4H)4+ = 866 m/z. 
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Figure B.14. HPLC purification of the CD52 32mer. The CD52 32mer was purified by 
RP-HPLC (Zorbax SB-C3 4.6 mm x 250 mm column, Agilent Technologies) with a 
gradient of 40-80% ACN over 40 min at 1 mL/min with 0.1% TFA in all solvents and the 
UV-visible detector was set to 254 nm. 
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Figure B.15. ESI mass spectrum of the purified of CD52 32mer. Exact mass = 3547 
g/mol. Observed (m+3H)3+ = 1184 m/z, (m+4H)4+ = 888 m/z, (m+5H)5+ = 711 m/z. 
Calculated (m+3H)3+ = 1183 m/z, (m+4H)4+ = 888 m/z, (m+5H)5+ = 710 m/z. 
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Figure B.16. HPLC purification of the CD52 34mer. The CD52 34mer was purified by 
RP-HPLC (Zorbax SB-C3 4.6 mm x 250 mm column, Agilent Technologies) with a 
gradient of 40-80% ACN over 40 min at 1 mL/min with 0.1% TFA in all solvents and the 
UV-visible detector was set to 254 nm. 
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Figure B.17. ESI mass spectrum of the purified of CD52 34mer. Exact mass = 3763 
g/mol. Observed (m+4H)3+ = 942 m/z, (m+5H)5+ = 754 m/z. Calculated (m+4H)3+ = 942 
m/z, (m+5H)5+ = 754 m/z. 
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Figure B.18. HPLC purification of the CD52 Abz-37mer. The CD52 Abz-37mer was 
purified by RP-HPLC (C18 Atlantis Prep T3 5.0 µm 10 mm x 250 mm column, Waters 
Corporation) with a gradient of 58-60% ACN over 20 min at 2 mL/min with 0.1% TFA in 
all solvents and the UV-visible detector was set to 321 nm. 
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Figure B.19. ESI mass spectrum of 10 µM Abz-37mer. Exact mass = 4195 g/mol. 
Observed (m+3H)3+ = 1400 m/z, (m+4H)4+ = 1050 m/z, (m+5H)5+ = 840 m/z. Calculated 
(m+3H)3+ = 1400 m/z, (m+4H)4+ = 1050 m/z, (m+5H)5+ = 840 m/z. 
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Figure B.20. ESI mass spectrum of 10 µM Abz-37mer Δ4. Exact mass = 3677 g/mol. 
Observed (m+3H)3+ = 1227 m/z, (m+4H)4+ = 920 m/z. Calculated (m+3H)3+ = 1227 m/z, 
(m+4H)4+ = 920 m/z. 
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Figure B.21. ESI mass spectrum of 10 µM Abz-37mer Δ8. Exact mass = 3201 g/mol. 
Observed (m+2H)2+ = 1602 m/z, (m+3H)3+ = 1068 m/z. Calculated (m+2H)2+ = 1602 m/z, 
(m+3H)3+ = 1068 m/z. 
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Figure B.22. ESI mass spectrum of 10 µM Abz-37mer Δ19. Exact mass = 2064 g/mol. 
Observed (m+2H)2+ = 1033 m/z, (m+3H)3+ = 689 m/z. Calculated (m+2H)2+ = 1033 m/z, 
(m+3H)3+ = 689 m/z. 
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Figure B.23. ESI mass spectrum of 10 µM Abz-37mer S12D. Exact mass = 4223 
g/mol. Observed (m+3H)3+ = 1409 m/z, (m+4H)4+ = 1057 m/z, (m+5H)5+ = 846 m/z. 
Calculated (m+3H)3+ = 1409 m/z, (m+4H)4+ = 1057 m/z, (m+5H)5+ = 846 m/z. 
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Figure B.24. ESI mass spectrum of 10 µM Abz-37mer S12R. Exact mass = 4264 
g/mol. Observed (m+3H)3+ = 1423 m/z, (m+4H)4+ = 1067 m/z, (m+5H)5+ = 854 m/z. 
Calculated (m+3H)3+ = 1422 m/z, (m+4H)4+ = 1067 m/z, (m+5H)5+ = 854 m/z. 
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Figure B.25. ESI mass spectrum of 10 µM Abz-12mer hydroxamic acid. Exact mass 
= 1384 g/mol. Observed (m+2H)2+ = 693 m/z. Calculated (m+2H)2+ = 693 m/z. 
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Figure B.26. Full ESI mass spectrum of the Abz-12mer hydroxamic acid purified 
from the crude assay mixture, with respect to Figure 2.7c. Exact mass = 1384 g/mol. 
Observed (m+2H)2+ = 693 m/z. Calculated (m+2H)2+ = 693 m/z. 
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Figure B.27. ESI mass spectrum of the Abz-12mer carboxylic acid purified from a 
crude assay mixture. Exact mass = 1369 g/mol. Observed (m+2H)2+ = 685 m/z. 
Calculated (m+2H)2+ = 685 m/z. 
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APPENDIX C TRIPLICATE DATA FROM EACH ASSAY PERFORMED WITH THE 
PURIFIED SOLUBLE GPI-T HETEROTRIMER 
 
Table C.1. Experimental conditions for the assays presented in Appendix C. This 
table lists the different peptide substrates used to assay the purified soluble GPI-T 
heterotrimer in the presence or absence of 10 mM NH2OH. 
 
Figure Peptide substrate used Assay conditions 
C.1 Abz-37mer No enzyme 
C.2 Abz-37mer No NH2OH (assay buffer) 
C.3 Abz-37mer 10 mM NH2OH 
C.4 Abz-37mer 10 mM NH2OH with leupeptin 
C.5 Abz-37mer Δ4 10 mM NH2OH 
C.6 Abz-37mer Δ8 10 mM NH2OH 
C.7 Abz-37mer Δ19 10 mM NH2OH 
C.8 Abz-37mer S12D 10 mM NH2OH 
C.9 Abz-37mer S12R 10 mM NH2OH 
 
Each assay was performed with 10 µM peptide substrate in assay buffer (see section 
2.4.1 for the optimized buffer). The peptide substrate was incubated in 1 mL assay buffer 
at room temperature for two min before the addition of purified soluble GPI-T 
heterotrimer. Each assay was initiated by the addition of enzyme to 1 µM and 
fluorescence was monitored for 10 min. For the no enzyme control assay, fluorescence 
of 10 µM Abz-37mer in assay buffer was monitored for 10 min.  
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Abz-GQKDTSEKSSPSωASKNY*SGGIFLFFVANAIIHLFHFS 
 
Figure C.1. Negative control assays were performed without the purified soluble 
GPI-T heterotrimer. Traces from three independent assays are shown with respect to 
Figure 2.7. 
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Abz-GQKDTSEKSSPSωASKNY*SGGIFLFFVANAIIHLFHFS 
 
Figure C.2. Assays performed without NH2OH. Traces from three independent assays 
are shown with respect to Figure 2.7. 
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Abz-GQKDTSEKSSPSωASKNY*SGGIFLFFVANAIIHLFHFS 
 
Figure C.3. Assays performed with 10 mM NH2OH. Traces from three independent 
assays are shown with respect to Figure 2.7. 
  
-2
0
2
4
6
8
10
12
0 2 4 6 8 10
Fl
uo
re
sc
en
ce
 In
te
ns
ity
 (a
.u
.)
Time (min)
109 
 
The use of 2-iodoacetamide, p-chloromercuribenzoate, and p-
chloromercuriphenylsulfonic acid inhibited trypanosomal GPI-T, to varying degrees, but 
did not inhibit the mammalian enzyme.66 Dr. Ekanayaka observed full-length GPI-T 
inhibition with 1 mM leupeptin.108 In vitro peptide cleavage assays were performed with 
the Abz-37mer peptide and purified soluble GPI-T heterotrimer in the presence and 
absence of leupeptin.  
Abz-GQKDTSEKSSPSωASKNY*SGGIFLFFVANAIIHLFHFS 
 
Figure C.4. Assays performed with the Abz-37mer peptide in the presence and 
absence of 1 mM leupeptin. Assays were performed using 10 µM Abz-37mer peptide 
in assay buffer with 10 mM NH2OH. The reaction was initiated with 1 µM purified soluble 
GPI-T heterotrimer that had been incubated with 1 mM leupeptin, a cysteine protease 
inhibitor, for 15 min at 4 °C before the assay.147 
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Abz-GQKDTSEKSSPSωASKNY*SGGIFLFFVANAIIHL 
 
Figure C.5. Assays performed with the Abz-37mer Δ4 peptide. Traces from three 
independent assays are shown with respect to Figure 2.8. 
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Abz-GQKDTSEKSSPSωASKNY*SGGIFLFFVANA 
 
Figure C.6. Assays performed with the Abz-37mer Δ8 peptide. Traces from three 
independent assays are shown with respect to Figure 2.8. 
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Abz-GQKDTSEKSSPSωASKNY*S 
 
Figure C.7. Assays performed with the Abz-37mer Δ19 peptide. Traces from three 
independent assays are shown with respect to Figure 2.8. 
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Abz-GQKDTSEKSSPDωASKNY*SGGIFLFFVANAIIHLFHFS 
 
Figure C.8. Assays performed with the Abz-37mer S12D peptide. Traces from three 
independent assays are shown with respect to Figure 2.9. 
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Abz-GQKDTSEKSSPRωASKNY*SGGIFLFFVANAIIHLFHFS 
 
Figure C.9. Assays performed with the Abz-37mer S12R peptide. Traces from three 
independent assays are shown with respect to Figure 2.9. 
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APPENDIX D THE MEMBRANE-SOLUBILIZED S. CEREVISIAE GPI-T RETAINS 
CATALYTIC ACTIVITY IN VITRO 
 
D.1 Introduction 
Fundamental biochemical research on GPI-T has been limited due to its poor 
expression and the lack of a method to measure purified enzyme activity. In recent 
years, our laboratory has reported97, 100 and this dissertation research further investigates 
methods to predict, design, and overexpress the soluble domains of the S. cerevisiae 
core GPI-T heterotrimer subunits to characterize its assembly. An in vitro peptide 
cleavage assay was also developed in our laboratory by Dr. Ekanayaka to measure the 
activity of the purified, membrane-solubilized GPI-T (briefly discussed in section 
1.5.3).108 Purified, full-length GPI-T remains catalytically active in time- and nucleophile-
dependent manners, consistent with transamidation activity. The full-length GPI-T also 
recognizes synthetic propeptide substrates and exhibits specificity at the ω-site, similar 
to in vivo results observed with the wild-type mammalian enzyme and those reported in 
this work in Chapter 2.75, 81 The assay data with the purified, full-length GPI-T complex is 
consistent with peptide cleavage and transamidation, but efforts to identify the expected 
hydroxamic acid peptide product were unsuccessful.108 This in vitro peptide cleavage 
assay was also used to show that a minimalistic, soluble GPI-T remains catalytically 
active (Chapter 2). At this point, peptide product characterization was optimized and 
performed using the simplified assay conditions optimized for the purified soluble GPI-T 
heterotrimer (Chapter 2). This appendix summarizes additional experiments performed 
to analyze peptide product formation from assays with the membrane-solubilized GPI-T. 
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D.2 Results 
D.2.1 Full-length GPI-T remains catalytically active in vitro  
Prior to the work presented in this dissertation, Dr. Ekanayaka developed and 
optimized the peptide cleavage assay with the purified S. cerevisiae GPI-T 
heterotrimer.108 GPI-T was purified as previously described from the gpi8 knockout yeast 
strain FBY656, provided by Prof. Andreas Conzelmann, which contains a plasmid that 
encodes for GST-Gpi8.11 The optimized full-length enzyme assay buffer contains 50 mM 
Tris pH 7.0, 100 mM NaCl, 200 mM mannitol, 1 mM MgCl2, 1 mM MnCl2, 1 mM CaCl2, 1 
mM DTT, 1 mM PMSF, 0.1% digitonin, and 20 mM reduced glutathione (GSH). While 
Gaa1 and Gpi16 are reported to co-purify with GST-Gpi8, these results have not been 
reproducible to an extent where all three subunits were visible in a silver-stained gel. 
Consequently, the concentration of the enzyme stock could not be calculated.11 Each 2 
mL assay was initiated by the addition of 50 µL purified enzyme in 50% glycerol. 
GPI-T accepts hydroxylamine and hydrazine as nucleophiles in vitro.65 Dr. 
Ekanayaka performed assays with 10 mM hydroxylamine or 10 mM hydrazine, and 
compared these assays to control experiments without added nucleophile to analyze the 
nucleophile-dependence of purified GPI-T.108 An increased fluorescence signal was 
observed with hydroxylamine and hydrazine compared to the no nucleophile control, 
consistent with peptide cleavage and transamidation.108 Purified GPI-T also recognized 
the C-terminal signal sequences of propeptide substrates and exhibited specificity at the 
ω-site, which demonstrates the full-length S. cerevisiae GPI-T heterotrimer retains 
activity in vitro similar to the mammalian enzyme in vivo.75, 81, 82 
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D.2.2 Initial analyses of crude assays performed with the purified, membrane-
solubilized GPI-T 
Prior to the development and optimization of assay analyses performed with the 
purified, minimalistic GPI-T, a modified form of the Abz-37mer peptide (biotin-37mer, 
Table D.1) was biotinylated near its N-terminus (Lys3) and was used as a substrate for 
assays to allow for streptavidin pull-down and characterization of the anticipated Abz-
12mer hydroxamic acid peptide product.67, 83 Using the optimized conditions developed 
by Dr. Ekanayaka,108 initial assays were performed with 10 µM biotin-37mer in full-length 
enzyme assay buffer in the presence and absence of 10 mM NH2OH and with and 
without 20 mM GSH (Figure D.1). An increased fluorescence signal over time was 
observed in the assay with 10 mM NH2OH, demonstrating nucleophile dependence, 
similar to previous results obtained by Dr. Ekayanaka.108 Changes in fluorescence signal 
were also observed for the no enzyme control and no nucleophile assays with 20 mM 
GSH, suggesting that GSH may be acting as a nucleophile, reacting with the activated 
thioester that forms between the peptide substrate and GPI-T, and allowing for 
hydrolysis of the peptide. The highest fluorescence signal was observed with the 10 mM 
NH2OH assay without glutathione, which supports peptide cleavage and transamidation. 
Continued efforts to pull-down and identify the expected biotinylated Abz-12mer 
hydroxamic acid peptide product were unsuccessful. At this point, assay analyses 
continued with the soluble GPI-T heterotrimer (Figure 2.5b-c). 
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Table D.1. Synthetic peptide substrates used to assay purified, full-length GPI-T. 
Abbreviations: Abz: 2-aminobenzoic acid, Y*: 3-nitrotyrosine. 
 
Peptide N-terminus Propeptide Sequence 
WT 
CD52 
+NH3 GQNDTSETSSPSωASSNISGGIFLFFVANAIIHLFCFS 
37mer Abz GQKDTSEKSSPSωASKNY*SGGIFLFFVANAIIHLFHFS 
Biotin-
37mer Abz GQK(Biotin)DTSEKSSPSωASKNY*SGGIFLFFVANAIIHLFHFS 
 
 
Figure D.1. In vitro peptide cleavage assays performed with biotin-37mer and 
purified full-length GPI-T. Assays were performed with 10 µM biotin-37mer in the 
presence or absence of 10 mM NH2OH (blue and red traces, respectively). Fluorescence 
was recorded after initiation with GPI-T, compared to no enzyme negative control assays 
(black). The full-length enzyme assay buffer with and without 20 mM GSH was used 
(closed and open circles, respectively). 
 
Peptide cleavage assays were repeated with 10 µM Abz-37mer in full-length enzyme 
assay buffer with 10 mM NH2OH in the absence of GSH at room temperature for 1 h 
after the addition of purified full-length GPI-T heterotrimer (Figure D.2). An increase in 
fluorescence was detected for 1 h, consistent with previous results. The crude assay 
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mixture was analyzed using the HPLC and ESI-MS methods described in section 2.4.10. 
A poor signal-to-noise ratio was observed during MS analyses, which prevented 
confirmation of the anticipated Abz-12mer hydroxamic acid product. 
 
Figure D.2. In vitro peptide cleavage assay performed with the Abz-37mer peptide 
substrate and purified full-length GPI-T. An assay was performed with 10 µM Abz-
37mer in full-length enzyme assay buffer with GSH and with 10 mM NH2OH. 
Fluorescence was recorded for 1 h after initiation with purified enzyme. 
 
The assay data shown in Figures D.1 and D.2 and the GPI-T characterization 
performed by Dr. Ekanayaka108 demonstrate that the purified, full-length GPI-T from S. 
cerevisiae retains catalytic activity. The membrane-solubilized GPI-T recognizes the C-
terminal signal sequence of propeptide substrates and exhibits specificity at the ω-site, 
similar to the results observed in sections 2.2.7-8, respectively, and with the wild-type 
mammalian enzyme.75, 81, 82 
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D.3 Discussion 
GPI anchoring of proteins is an essential eukaryotic post-translational modification.4 
The dissertation research discussed in Chapter 2, as well as the data published on the 
development of an assay to characterize purified, full-length GPI-T from S. cerevisiae, 
shows significant progress towards gaining a better understanding of this enzyme’s 
function.108 This in vitro assay enables us to investigate the roles of each individual 
subunit and how their expression affects GPI-T activity. Gaining the ability to investigate 
the functions of each individual GPI-T subunit is important and provides new tools to 
better understand this enzyme’s role in cancer. 
D.4 Materials and methods 
D.4.1 Purification of GST-Gpi8 from yeast 
The protocols used to grow the gpi8-knockout yeast strain FBY656, and solubilize 
and purify GST-Gpi8 were developed and described by Dr. Sandamali A. Ekanayaka.108 
D.4.2 Peptide synthesis 
Refer to section 2.4.7 for the synthesis and purification of the Abz-37mer peptide 
substrate. After the synthesis of the CD52 Fmoc-25mer peptide, the resin was divided in 
two equal amounts. The Abz-37mer peptide synthesis continued on 250 mg of resin with 
the addition of N-(1-(4,4-dimethyl-2,6-dioxocyclohexylidene)ethyl) (Dde-protected) 
Fmoc-Lys-OH at Lys3 versus Boc-protected Fmoc-Lys-OH to enable biotinylation at the 
ε-amino group of this residue.148 
D.4.3 Abz-37mer biotinylation and purification 
For every 100 mg of 2-(Boc-amino)benzoic acid-37mer (Boc-Abz-37mer) peptide on 
resin, the Dde protecting group was removed by the addition of 1 mL 2% hydrazine 
hydrate/NMP with stirring for 20 min at room temperature.148 This resin was washed 3X 
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with 1 mL NMP. D-biotin was coupled to Lys3 on the resin with a solution of 1 mL 100 
mM D-biotin/DMSO and 1 mL 100 mM HBTU, 200 mM DIPEA/NMP for 2 h. Biotin 
coupling was verified by Kaiser tests and additional coupling reactions were performed 
when necessary.140 
The biotin-37mer peptide was purified using RP-HPLC (Zorbax SB-C3 4.6 x 250 mm, 
Agilent Technologies) with a gradient of 50-55% ACN over 5 min at 0.5 mL/min with 
0.1% TFA in each solvent. The peptide was confirmed by ESI-MS. Calculated mass of 
the biotin-37mer: 4421 g/mol; calculated (m+3H+)3+ = 1475 m/z, observed 1475 m/z; 
calculated (m+4H+)4+ = 1106 m/z, observed 1106 m/z; calculated (m+5H+)5+ = 885 m/z, 
observed 885 m/z. 
D.4.4 In vitro peptide cleavage assays 
The biotin-37mer or Abz-37mer peptide (10 µM from a 1 mM stock solution in 
DMSO) was incubated in full-length enzyme assay buffer (freshly prepared before each 
assay) for two min at room temperature prior to reaction initiation. Fluorescence intensity 
was measured after the addition of solubilized GPI-T heterotrimer at room temperature 
for 30 min every 10 s (Figure D.1) or 1 h every 1 s (Figure D.2) with an excitation 
wavelength of 321 nm and an emission wavelength of 417 nm.  
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Glycosylphosphatidylinositol (GPI) anchoring of proteins is a eukaryotic, post-
translational modification catalyzed by GPI transamidase (GPI-T). The Saccharomyces 
cerevisiae GPI-T is composed of five membrane-bound subunits: Gaa1, Gpi8, Gpi16, 
Gpi17, and Gab1. Structural and functional studies have been hindered by the 
complexity of this enzyme. Conditions to purify the Gpi8:Gaa1:Gpi16 GPI-T heterotrimer 
from yeast have been reported, but an understanding of the subunit functions, 
interactions, and stoichiometry remain unclear. Furthermore, a reliable, quantitative, in 
vitro assay for this important post-translational modification has remained elusive for 
nearly three decades.  
Our laboratory has developed an in vitro peptide cleavage assay that correlates 
changes in fluorescence to GPI-T activity. Using this peptide cleavage assay, it was 
demonstrated that the purified, full-length GPI-T retains activity, providing the first 
method to measure GPI-T activity in a quantitative, time-dependent manner.  
This dissertation research presents the characterization of the soluble domains of the 
GPI-T heterotrimeric complex, composed of Gpi823-306, Gaa150-343, and Gpi1620-551. Each 
soluble domain interacts with one another without the need for the third subunit. This 
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soluble GPI-T heterotrimer can be purified as one complex without its transmembrane 
domains. Most importantly, this simplified heterotrimer retains transamidase activity, 
demonstrating that these three subunits comprise the functional core of GPI-T. 
These results contribute to our understanding of how this enzyme is structurally 
organized, provide a method to screen potential GPI-T inhibitors, and open the door to 
further understand how GPI-T is involved in normal cellular function and pathogenesis. 
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